Scaling without slippage
Revenue up 54.0% YoY while gross margin expanded +259.9pp TTM to 340.1%
Frame pre-revenue biotech around cash runway, burn, and pipeline optionality instead of near-term profitability.
Pre-revenue biotech is not a margin story. It is a survival-and-optionality story shaped by cash runway, burn rate, R&D intensity, financing risk, and the value of future pipeline outcomes. The StatsAlpha(TM) biotech framework is designed to make that reality visible through runway-focused money flow, selective peer context, and a deliberately cautious analytical stance. It is for informational purposes only, not investment advice.
A quick read on where this framework looks strongest today.
Top slices selected from the strongest data already available for this industry.
Top 5 companies by current framework view
Recurring storylines, tone distribution, and representative beats pulled from active companies inside this setup.
Revenue up 54.0% YoY while gross margin expanded +259.9pp TTM to 340.1%
Revenue up 232.6% YoY while gross margin expanded +20.7pp TTM to 100.0%
Revenue up 30.2% YoY while gross margin expanded +26.1pp TTM to 97.9%
For informational purposes only. Not investment advice.
Metrics that recur most often across stronger operators in this framework.
Pre-Revenue Biotech
This framework softens or disables Profitability in the Trade-Off Ledger lens.
Each axis sets a minimum evidence threshold. Higher coverage means the framework needs more supporting signals before the lens is treated as dependable.
Coverage thresholds and enabled metrics across the core trade-off axes.
Median and interquartile range across 1022 companies in this framework.
Interquartile ranges show where the middle half of companies cluster, with the median pin marking the center of gravity for each pillar.
Scan the full company universe mapped into the Biotech / Pre-Revenue framework using live search across company name, ticker, and industry.
| Company | Market Cap | Score | Price | Strongest Pillar |
|---|---|---|---|---|
|
Biotechnology
|
126.01B
|
71.9
Composite
|
$496.07
|
Profitability
84.9
|
|
Biotechnology
|
70.90B
|
69.4
Composite
|
$784.36
|
Profitability
84.0
|
|
ARGX
argenx SE
Biotechnology
|
56.71B
|
69.2
Composite
|
$865.04
|
Profitability
86.3
|
|
Biotechnology
|
41.76B
|
74.6
Composite
|
$219.20
|
Valuation
92.2
|
|
Biotechnology
|
40.63B
|
47.9
Composite
|
$205.15
|
Efficiency
62.1
|
|
ONC
BeiGene, Ltd.
Biotechnology
|
33.67B
|
72.4
Composite
|
$348.27
|
Valuation
88.2
|
|
RPRX
Royalty Pharma plc
Biotechnology
|
33.38B
|
74.5
Composite
|
$56.77
|
Valuation
89.2
|
|
MRNA
Moderna, Inc.
Biotechnology
|
30.38B
|
50.6
Composite
|
$59.17
|
Profitability
66.8
|
|
Biotechnology
|
26.48B
|
45.4
Composite
|
$36.34
|
Health
58.7
|
|
INSM
Insmed Incorporated
Biotechnology
|
25.63B
|
59.3
Composite
|
$131.10
|
Profitability
69.3
|
|
INCY
Incyte Corporation
Biotechnology
|
23.68B
|
73.9
Composite
|
$120.56
|
Profitability
85.4
|
|
BNTX
BioNTech SE
Biotechnology
|
23.51B
|
51.1
Composite
|
$93.67
|
Profitability
68.2
|
|
Biotechnology
|
23.45B
|
70.0
Composite
|
$538.84
|
Profitability
84.1
|
|
GMAB
Genmab A/S
Biotechnology
|
19.13B
|
65.4
Composite
|
$31.25
|
Profitability
83.8
|
|
Biotechnology
|
17.68B
|
52.9
Composite
|
$84.48
|
Profitability
63.6
|
|
ASND
Ascendis Pharma A/S
Biotechnology
|
17.11B
|
64.7
Composite
|
$255.41
|
Profitability
81.3
|
|
Biotechnology
|
15.59B
|
76.8
Composite
|
$256.56
|
Valuation
83.8
|
|
EXEL
Exelixis, Inc.
Biotechnology
|
14.35B
|
72.8
Composite
|
$54.07
|
Valuation
88.0
|
|
Biotechnology
|
12.91B
|
60.2
Composite
|
$510.04
|
Profitability
72.8
|
|
Biotechnology
|
12.75B
|
57.0
Composite
|
$212.74
|
Profitability
69.5
|
|
ABVX
Abivax SA
Biotechnology
|
12.08B
|
50.9
Composite
|
$130.93
|
Profitability
60.6
|
|
Biotechnology
|
12.01B
|
55.4
Composite
|
$13.96
|
Profitability
68.6
|
|
Biotechnology
|
11.83B
|
63.0
Composite
|
$87.65
|
Profitability
73.4
|
|
Biotechnology
|
11.59B
|
68.5
Composite
|
$63.81
|
Profitability
82.0
|
|
TECH
Bio-Techne Corp
Biotechnology
|
11.09B
|
72.0
Composite
|
$72.29
|
Valuation
84.0
|
|
Biotechnology
|
11.07B
|
77.0
Composite
|
$326.45
|
Valuation
91.9
|
|
Biotechnology
|
10.62B
|
55.9
Composite
|
$56.56
|
Profitability
68.5
|
|
Biotechnology
|
10.56B
|
45.5
Composite
|
$76.76
|
Profitability
56.5
|
|
Biotechnology
|
10.01B
|
61.9
Composite
|
$134.84
|
Profitability
72.0
|
|
Biotechnology
|
10.01B
|
60.0
Composite
|
$110.77
|
Profitability
82.4
|
|
NUVL
Nuvalent, Inc.
Biotechnology
|
9.82B
|
59.3
Composite
|
$123.96
|
Profitability
76.6
|
|
Biotechnology
|
9.39B
|
54.7
Composite
|
$107.52
|
Profitability
75.1
|
|
Biotechnology
|
9.33B
|
75.2
Composite
|
$103.12
|
Profitability
83.8
|
|
IBRX
ImmunityBio, Inc.
Biotechnology
|
9.29B
|
47.7
Composite
|
$7.64
|
Profitability
57.5
|
|
Biotechnology
|
9.29B
|
45.0
Composite
|
$360.76
|
Profitability
53.4
|
|
Biotechnology
|
8.89B
|
66.4
Composite
|
$49.76
|
Profitability
82.9
|
|
Biotechnology
|
8.85B
|
68.7
Composite
|
$145.87
|
Profitability
82.5
|
|
Biotechnology
|
8.82B
|
56.1
Composite
|
$84.08
|
Profitability
62.7
|
|
PCVX
Vaxcyte, Inc.
Biotechnology
|
8.64B
|
54.5
Composite
|
$58.07
|
Profitability
62.4
|
|
Biotechnology
|
8.58B
|
57.9
Composite
|
$104.91
|
Profitability
68.3
|
|
IMVT
Immunovant, Inc.
Biotechnology
|
8.44B
|
51.1
Composite
|
$39.95
|
Health
66.2
|
|
Biotechnology
|
7.91B
|
56.5
Composite
|
$115.63
|
Profitability
70.9
|
|
Biotechnology
|
7.79B
|
53.0
Composite
|
$100.65
|
Efficiency
59.7
|
|
MTSR
Metsera, Inc.
Biotechnology
|
7.43B
|
0.0
Composite
|
$70.50
|
No pillar score
-
|
|
Biotechnology
|
7.43B
|
59.3
Composite
|
$73.31
|
Profitability
80.0
|
|
LQDA
Liquidia Corporation
Biotechnology
|
7.24B
|
81.0
Composite
|
$90.22
|
Valuation
92.5
|
|
Biotechnology
|
6.94B
|
56.0
Composite
|
$52.92
|
Profitability
66.5
|
|
Biotechnology
|
6.92B
|
57.3
Composite
|
$42.39
|
Profitability
63.0
|
|
Biotechnology
|
6.86B
|
52.6
Composite
|
$63.36
|
Health
69.6
|
|
ACLX
Arcellx, Inc.
Biotechnology
|
6.75B
|
50.3
Composite
|
$115.07
|
Profitability
61.1
|
|
CGON
CG Oncology, Inc.
Biotechnology
|
6.47B
|
53.6
Composite
|
$75.10
|
Health
59.4
|
|
Biotechnology
|
6.39B
|
66.1
Composite
|
$293.15
|
Profitability
79.4
|
|
Biotechnology
|
6.27B
|
56.4
Composite
|
$40.50
|
Profitability
65.3
|
|
Biotechnology
|
6.11B
|
56.2
Composite
|
$52.95
|
Health
67.9
|
|
ERAS
Erasca, Inc.
Biotechnology
|
5.96B
|
55.8
Composite
|
$18.41
|
Profitability
63.3
|
|
BLTE
Belite Bio, Inc
Biotechnology
|
5.80B
|
56.9
Composite
|
$163.05
|
Profitability
76.6
|
|
CELC
Celcuity Inc.
Biotechnology
|
5.54B
|
49.4
Composite
|
$92.78
|
Efficiency
61.2
|
|
Biotechnology
|
5.47B
|
56.2
Composite
|
$108.92
|
Health
72.2
|
|
Biotechnology
|
5.44B
|
64.1
Composite
|
$61.32
|
Profitability
75.9
|
|
Biotechnology
|
5.43B
|
47.0
Composite
|
$53.52
|
Health
67.9
|
|
ORKA
ARCA biopharma Inc
Biotechnology
|
5.32B
|
59.4
Composite
|
$98.82
|
Profitability
77.3
|
|
Biotechnology
|
5.30B
|
61.2
Composite
|
$20.75
|
Profitability
77.2
|
|
Biotechnology
|
5.25B
|
65.0
Composite
|
$41.03
|
Profitability
79.3
|
|
Biotechnology
|
5.20B
|
55.1
Composite
|
$43.52
|
Profitability
65.6
|
|
Biotechnology
|
4.78B
|
44.6
Composite
|
$34.26
|
Efficiency
66.3
|
|
Biotechnology
|
4.55B
|
67.6
Composite
|
$14.49
|
Profitability
77.3
|
|
Biotechnology
|
4.52B
|
69.6
Composite
|
$29.21
|
Profitability
83.3
|
|
Biotechnology
|
4.52B
|
52.4
Composite
|
$19.77
|
Health
61.1
|
|
Biotechnology
|
4.41B
|
58.2
Composite
|
$27.07
|
Profitability
76.2
|
|
Biotechnology
|
4.32B
|
56.6
Composite
|
$24.83
|
Profitability
72.1
|
|
Biotechnology
|
4.20B
|
54.5
Composite
|
$27.96
|
Profitability
64.1
|
|
Biotechnology
|
4.01B
|
51.0
Composite
|
$26.25
|
Profitability
55.4
|
|
Biotechnology
|
3.99B
|
67.1
Composite
|
$11.52
|
Profitability
81.7
|
|
Biotechnology
|
3.92B
|
60.4
Composite
|
$53.14
|
Valuation
67.5
|
|
Biotechnology
|
3.85B
|
71.2
Composite
|
$31.49
|
Valuation
85.6
|
|
Biotechnology
|
3.81B
|
51.3
Composite
|
$28.62
|
Profitability
62.6
|
|
ALMS
Alumis Inc.
Biotechnology
|
3.79B
|
47.3
Composite
|
$27.60
|
Growth
66.7
|
|
Biotechnology
|
3.64B
|
56.7
Composite
|
$60.46
|
Health
67.8
|
|
Biotechnology
|
3.60B
|
70.3
Composite
|
$25.29
|
Profitability
80.4
|
|
Biotechnology
|
3.57B
|
55.4
Composite
|
$27.48
|
Profitability
70.8
|
|
Biotechnology
|
3.54B
|
58.1
Composite
|
$37.02
|
Profitability
64.6
|
|
Biotechnology
|
3.49B
|
63.0
Composite
|
$24.93
|
Profitability
78.7
|
|
Biotechnology
|
3.40B
|
54.5
Composite
|
$25.91
|
Profitability
71.4
|
|
Biotechnology
|
3.13B
|
63.5
Composite
|
$67.82
|
Profitability
77.0
|
|
Biotechnology
|
3.06B
|
49.0
Composite
|
$41.71
|
Health
60.0
|
|
Biotechnology
|
3.05B
|
48.6
Composite
|
$32.89
|
Profitability
64.7
|
|
IRON
Disc Medicine, Inc.
Biotechnology
|
3.00B
|
56.6
Composite
|
$77.44
|
Profitability
79.5
|
|
Biotechnology
|
2.76B
|
74.9
Composite
|
$53.01
|
Valuation
87.0
|
|
Biotechnology
|
2.76B
|
65.8
Composite
|
$64.79
|
Profitability
82.4
|
|
QURE
uniQure N.V.
Biotechnology
|
2.74B
|
55.0
Composite
|
$46.42
|
Profitability
62.0
|
|
IMNM
Immunome, Inc.
Biotechnology
|
2.74B
|
54.2
Composite
|
$25.03
|
Efficiency
68.7
|
|
Biotechnology
|
2.72B
|
52.4
Composite
|
$9.38
|
Efficiency
61.4
|
|
Biotechnology
|
2.69B
|
63.9
Composite
|
$27.35
|
Profitability
75.4
|
|
Biotechnology
|
2.61B
|
52.0
Composite
|
$18.51
|
Efficiency
65.0
|
|
Biotechnology
|
2.55B
|
50.6
Composite
|
$25.53
|
Profitability
58.7
|
|
Biotechnology
|
2.54B
|
52.3
Composite
|
$32.27
|
Profitability
67.5
|
|
BHVN
Biohaven Ltd.
Biotechnology
|
2.53B
|
54.6
Composite
|
$14.66
|
Profitability
67.0
|
|
Biotechnology
|
2.51B
|
60.2
Composite
|
$12.01
|
Valuation
69.5
|
|
PHVS
Pharvaris N.V.
Biotechnology
|
2.51B
|
52.9
Composite
|
$34.91
|
Profitability
72.5
|
|
Biotechnology
|
2.50B
|
46.5
Composite
|
$45.37
|
Profitability
60.1
|
|
VCEL
Vericel Corporation
Biotechnology
|
2.47B
|
69.4
Composite
|
$45.09
|
Profitability
80.5
|
|
NKTR
Nektar Therapeutics
Biotechnology
|
2.46B
|
55.8
Composite
|
$76.48
|
Profitability
70.2
|
|
Biotechnology
|
2.31B
|
55.0
Composite
|
$9.19
|
Profitability
65.0
|
|
ZLAB
Zai Lab Limited
Biotechnology
|
2.24B
|
55.0
Composite
|
$23.32
|
Profitability
73.7
|
|
Biotechnology
|
2.23B
|
56.9
Composite
|
$6.93
|
Profitability
73.8
|
|
Biotechnology
|
2.22B
|
59.7
Composite
|
$21.53
|
Efficiency
75.7
|
|
Biotechnology
|
2.20B
|
70.2
Composite
|
$38.41
|
Valuation
83.0
|
|
Biotechnology
|
2.20B
|
57.4
Composite
|
$20.40
|
Profitability
73.2
|
|
Biotechnology
|
2.17B
|
63.1
Composite
|
$16.78
|
Profitability
78.9
|
|
Biotechnology
|
2.16B
|
52.8
Composite
|
$11.94
|
Profitability
64.0
|
|
ADMA
ADMA Biologics Inc
Biotechnology
|
2.15B
|
68.8
Composite
|
$9.90
|
Profitability
82.6
|
|
Biotechnology
|
2.13B
|
73.0
Composite
|
$15.85
|
Valuation
87.0
|
|
NUVB
Nuvation Bio Inc.
Biotechnology
|
2.13B
|
72.7
Composite
|
$6.60
|
Valuation
87.6
|
|
Biotechnology
|
2.10B
|
54.8
Composite
|
$6.56
|
Profitability
68.1
|
|
Biotechnology
|
2.08B
|
54.9
Composite
|
$157.77
|
Health
68.2
|
|
Biotechnology
|
2.08B
|
47.6
Composite
|
$23.59
|
Growth
55.9
|
|
Biotechnology
|
2.07B
|
55.6
Composite
|
$15.88
|
Profitability
67.6
|
|
Biotechnology
|
2.04B
|
56.0
Composite
|
$32.71
|
Profitability
70.0
|
|
Biotechnology
|
2.04B
|
54.8
Composite
|
$22.82
|
Profitability
69.8
|
|
Biotechnology
|
2.03B
|
54.2
Composite
|
$51.04
|
Profitability
77.9
|
|
Biotechnology
|
2.01B
|
63.0
Composite
|
$45.49
|
Profitability
81.4
|
|
Biotechnology
|
2.00B
|
47.0
Composite
|
$3.22
|
Profitability
54.4
|
|
NBTX
Nanobiotix S.A.
Biotechnology
|
1.98B
|
49.1
Composite
|
$38.22
|
Profitability
64.7
|
|
ANAB
AnaptysBio, Inc.
Biotechnology
|
1.97B
|
53.1
Composite
|
$56.61
|
Health
60.0
|
|
PGEN
Precigen, Inc.
Biotechnology
|
1.96B
|
54.4
Composite
|
$7.23
|
Profitability
67.2
|
|
Biotechnology
|
1.96B
|
52.7
Composite
|
$26.51
|
Health
63.4
|
|
Biotechnology
|
1.96B
|
50.0
Composite
|
$7.25
|
Growth
65.1
|
|
Biotechnology
|
1.95B
|
59.2
Composite
|
$6.34
|
Profitability
70.8
|
|
GLPG
Galapagos NV
Biotechnology
|
1.95B
|
61.2
Composite
|
$29.60
|
Profitability
75.1
|
|
ABSI
Absci Corporation
Biotechnology
|
1.94B
|
45.8
Composite
|
$8.93
|
Profitability
50.1
|
|
MESO
Mesoblast Limited
Biotechnology
|
1.91B
|
53.7
Composite
|
$15.94
|
Profitability
64.8
|
|
ZYME
Zymeworks Inc.
Biotechnology
|
1.91B
|
51.6
Composite
|
$23.54
|
Efficiency
63.8
|
|
Biotechnology
|
1.90B
|
53.4
Composite
|
$28.06
|
Profitability
74.6
|
|
GHRS
GH Research PLC
Biotechnology
|
1.87B
|
51.7
Composite
|
$30.27
|
Profitability
79.7
|
|
Biotechnology
|
1.86B
|
50.4
Composite
|
$32.43
|
Health
62.7
|
|
URGN
UroGen Pharma Ltd.
Biotechnology
|
1.85B
|
54.4
Composite
|
$46.96
|
Profitability
72.6
|
|
Biotechnology
|
1.79B
|
60.2
Composite
|
$58.01
|
Profitability
75.7
|
|
Biotechnology
|
1.77B
|
62.4
Composite
|
$28.65
|
Profitability
79.5
|
|
Biotechnology
|
1.75B
|
49.3
Composite
|
$18.09
|
Efficiency
85.4
|
|
Biotechnology
|
1.74B
|
48.3
Composite
|
$8.82
|
Profitability
71.3
|
|
Biotechnology
|
1.68B
|
61.0
Composite
|
$34.00
|
Profitability
80.5
|
|
Biotechnology
|
1.67B
|
66.6
Composite
|
$18.43
|
Profitability
76.1
|
|
Shell Companies
|
1.67B
|
58.1
Composite
|
$18.83
|
Growth
87.6
|
|
Biotechnology
|
1.65B
|
48.0
Composite
|
$18.26
|
Valuation
59.5
|
|
SEPN
Septerna, Inc.
Biotechnology
|
1.64B
|
65.0
Composite
|
$38.83
|
Profitability
83.2
|
|
INVA
Innoviva, Inc.
Biotechnology
|
1.64B
|
74.8
Composite
|
$20.51
|
Valuation
85.3
|
|
Biotechnology
|
1.60B
|
53.8
Composite
|
$18.98
|
Profitability
60.8
|
|
Biotechnology
|
1.57B
|
65.6
Composite
|
$30.84
|
Profitability
75.2
|
|
NVAX
Novavax, Inc.
Biotechnology
|
1.55B
|
51.1
Composite
|
$7.95
|
Profitability
76.8
|
|
Biotechnology
|
1.54B
|
70.7
Composite
|
$6.23
|
Profitability
76.6
|
|
Biotechnology
|
1.52B
|
41.7
Composite
|
$88.66
|
Health
48.5
|
|
GLTO
Galecto, Inc.
Biotechnology
|
1.49B
|
56.6
Composite
|
$24.99
|
Valuation
66.6
|
|
Biotechnology
|
1.49B
|
71.8
Composite
|
$7.93
|
Valuation
80.8
|
|
Biotechnology
|
1.44B
|
53.0
Composite
|
$27.00
|
Profitability
68.9
|
|
IMTX
Immatics N.V.
Biotechnology
|
1.36B
|
51.8
Composite
|
$9.65
|
Profitability
71.3
|
|
Biotechnology
|
1.36B
|
57.0
Composite
|
$13.92
|
Growth
69.0
|
|
ARDX
Ardelyx, Inc.
Biotechnology
|
1.33B
|
60.5
Composite
|
$4.00
|
Profitability
75.1
|
|
SVRA
Savara, Inc.
Biotechnology
|
1.31B
|
55.1
Composite
|
$5.83
|
Profitability
71.9
|
|
Biotechnology
|
1.30B
|
57.3
Composite
|
$4.09
|
Profitability
74.1
|
|
Biotechnology
|
1.29B
|
48.7
Composite
|
$13.07
|
Efficiency
100.0
|
|
MNKD
MannKind Corporation
Biotechnology
|
1.28B
|
60.1
Composite
|
$4.11
|
Profitability
81.7
|
|
Biotechnology
|
1.24B
|
40.9
Composite
|
$13.89
|
Efficiency
54.1
|
|
Biotechnology
|
1.21B
|
61.1
Composite
|
$6.10
|
Profitability
78.4
|
|
XNCR
Xencor, Inc.
Biotechnology
|
1.19B
|
49.9
Composite
|
$20.81
|
Valuation
55.6
|
|
Biotechnology
|
1.18B
|
54.3
Composite
|
$3.52
|
Profitability
61.6
|
|
Biotechnology
|
1.17B
|
55.1
Composite
|
$13.14
|
Efficiency
69.5
|
|
Biotechnology
|
1.13B
|
59.2
Composite
|
$13.50
|
Growth
65.5
|
|
Biotechnology
|
1.13B
|
54.2
Composite
|
$17.73
|
Profitability
71.8
|
|
Biotechnology
|
1.10B
|
55.0
Composite
|
$8.39
|
Profitability
70.4
|
|
KURA
Kura Oncology, Inc.
Biotechnology
|
1.08B
|
52.7
Composite
|
$9.57
|
Profitability
67.4
|
|
Biotechnology
|
1.07B
|
57.5
Composite
|
$12.05
|
Profitability
65.6
|
|
Biotechnology
|
1.07B
|
50.2
Composite
|
$23.67
|
Profitability
66.0
|
|
CVAC
CureVac N.V.
Biotechnology
|
1.05B
|
67.8
Composite
|
$4.66
|
Profitability
85.8
|
|
Biotechnology
|
1.02B
|
56.4
Composite
|
$15.85
|
Profitability
74.6
|
|
Biotechnology
|
1.02B
|
65.5
Composite
|
$4.63
|
Profitability
86.0
|
|
Biotechnology
|
1.01B
|
37.4
Composite
|
$4.80
|
Health
46.6
|
|
PHAR
Pharming Group N.V.
Biotechnology
|
1.01B
|
65.8
Composite
|
$10.95
|
Profitability
79.4
|
|
Biotechnology
|
1.01B
|
45.8
Composite
|
$18.32
|
Health
54.0
|
|
Biotechnology
|
1.00B
|
51.9
Composite
|
$14.00
|
Valuation
56.8
|
|
GERN
Geron Corporation
Biotechnology
|
1.00B
|
65.2
Composite
|
$1.48
|
Profitability
79.8
|
|
Biotechnology
|
999.40M
|
65.7
Composite
|
$2.47
|
Profitability
79.5
|
|
Shell Companies
|
990.77M
|
57.2
Composite
|
$26.11
|
Growth
67.7
|
|
ANNX
Annexon, Inc.
Biotechnology
|
973.22M
|
56.9
Composite
|
$5.41
|
Profitability
67.9
|
|
Biotechnology
|
970.00M
|
55.8
Composite
|
$28.67
|
Efficiency
62.0
|
|
Biotechnology
|
965.87M
|
58.0
Composite
|
$8.55
|
Profitability
74.6
|
|
Biotechnology
|
954.34M
|
56.2
Composite
|
$13.99
|
Profitability
66.3
|
|
Biotechnology
|
952.10M
|
51.5
Composite
|
$13.48
|
Growth
60.5
|
|
Shell Companies
|
937.42M
|
39.8
Composite
|
$5.33
|
Health
46.0
|
|
Biotechnology
|
936.00M
|
45.2
Composite
|
$13.44
|
Health
48.8
|
|
Biotechnology
|
933.47M
|
48.6
Composite
|
$12.06
|
Valuation
57.5
|
|
Biotechnology
|
896.79M
|
49.5
Composite
|
$76.79
|
Health
59.0
|
|
Biotechnology
|
880.04M
|
67.5
Composite
|
$16.93
|
Profitability
79.9
|
|
Biotechnology
|
861.00M
|
56.6
Composite
|
$3.46
|
Profitability
78.8
|
|
NGNE
Neurogene Inc.
Biotechnology
|
853.67M
|
46.3
Composite
|
$35.69
|
Efficiency
53.4
|
|
Biotechnology
|
827.32M
|
47.1
Composite
|
$12.68
|
Growth
53.0
|
|
Biotechnology
|
824.06M
|
69.8
Composite
|
$11.56
|
Profitability
83.0
|
|
Biotechnology
|
809.65M
|
72.6
Composite
|
$40.17
|
Valuation
84.7
|
|
RGNX
REGENXBIO Inc.
Biotechnology
|
809.10M
|
49.1
Composite
|
$10.72
|
Valuation
64.9
|
|
CLYM
Climb Bio, Inc.
Biotechnology
|
791.34M
|
52.4
Composite
|
$14.00
|
Profitability
76.0
|
|
Biotechnology
|
789.50M
|
50.2
Composite
|
$9.72
|
Growth
64.1
|
|
Biotechnology
|
782.51M
|
57.8
Composite
|
$6.16
|
Profitability
69.4
|
|
Biotechnology
|
772.10M
|
55.4
Composite
|
$7.99
|
Profitability
65.9
|
|
Biotechnology
|
764.81M
|
65.5
Composite
|
$6.67
|
Profitability
82.8
|
|
PRME
Prime Medicine, Inc.
Biotechnology
|
764.01M
|
46.2
Composite
|
$3.08
|
Valuation
56.6
|
|
OMER
Omeros Corporation
Biotechnology
|
743.30M
|
56.8
Composite
|
$13.25
|
Profitability
76.0
|
|
Biotechnology
|
724.82M
|
49.1
Composite
|
$2.01
|
Valuation
56.1
|
|
Biotechnology
|
724.64M
|
60.5
Composite
|
$10.59
|
Profitability
73.6
|
|
Biotechnology
|
718.10M
|
49.7
Composite
|
$12.58
|
Health
51.8
|
|
Shell Companies
|
705.82M
|
41.9
Composite
|
$11.41
|
Profitability
51.1
|
|
Biotechnology
|
700.02M
|
65.0
Composite
|
$119.21
|
Growth
85.0
|
|
Biotechnology
|
682.84M
|
70.1
Composite
|
$4.94
|
Growth
81.3
|
|
CRMD
CorMedix Inc.
Biotechnology
|
680.18M
|
76.1
Composite
|
$7.44
|
Profitability
84.5
|
|
Biotechnology
|
673.84M
|
56.6
Composite
|
$10.75
|
Growth
65.6
|
|
Biotechnology
|
665.52M
|
50.9
Composite
|
$30.98
|
Profitability
76.8
|
|
Biotechnology
|
663.93M
|
56.2
Composite
|
$79.33
|
Profitability
82.5
|
|
Biotechnology
|
657.02M
|
55.6
Composite
|
$6.65
|
Profitability
66.6
|
|
Biotechnology
|
635.61M
|
48.2
Composite
|
$7.97
|
Profitability
66.8
|
|
MDXG
MiMedx Group, Inc
Biotechnology
|
616.64M
|
62.1
Composite
|
$4.34
|
Profitability
80.1
|
|
Biotechnology
|
609.93M
|
43.9
Composite
|
$25.96
|
Profitability
59.9
|
|
ALT
Altimmune, Inc.
Biotechnology
|
606.76M
|
52.5
Composite
|
$3.08
|
Health
60.9
|
|
Biotechnology
|
598.67M
|
61.5
Composite
|
$18.95
|
Profitability
72.6
|
|
Biotechnology
|
596.40M
|
54.8
Composite
|
$7.96
|
Profitability
73.1
|
|
Biotechnology
|
577.62M
|
60.5
Composite
|
$15.04
|
Profitability
81.3
|
|
Biotechnology
|
561.80M
|
76.3
Composite
|
$40.17
|
Valuation
92.4
|
|
ARVN
Arvinas, Inc.
Biotechnology
|
551.01M
|
52.0
Composite
|
$8.75
|
Profitability
71.9
|
|
PROK
ProKidney Corp.
Biotechnology
|
543.70M
|
47.4
Composite
|
$1.64
|
Efficiency
68.7
|
|
STTK
Shattuck Labs, Inc.
Biotechnology
|
539.06M
|
55.3
Composite
|
$7.27
|
Health
60.6
|
|
ZURA
Zura Bio Limited
Biotechnology
|
521.54M
|
58.5
Composite
|
$5.96
|
Profitability
77.6
|
|
Biotechnology
|
515.70M
|
72.0
Composite
|
$8.76
|
Profitability
81.0
|
|
CABA
Cabaletta Bio, Inc.
Biotechnology
|
507.92M
|
57.5
Composite
|
$2.79
|
Profitability
65.3
|
|
Biotechnology
|
507.79M
|
59.8
Composite
|
$4.90
|
Profitability
74.6
|
|
Biotechnology
|
506.42M
|
52.1
Composite
|
$2.88
|
Valuation
59.4
|
|
OCGN
Ocugen, Inc.
Biotechnology
|
497.63M
|
51.2
Composite
|
$1.28
|
Health
61.5
|
|
Biotechnology
|
496.95M
|
51.6
Composite
|
$25.38
|
Profitability
74.2
|
|
VALN
Valneva SE
Biotechnology
|
495.80M
|
54.6
Composite
|
$5.30
|
Profitability
66.6
|
|
Biotechnology
|
485.26M
|
58.9
Composite
|
$2.63
|
Profitability
75.7
|
|
RZLT
Rezolute, Inc.
Biotechnology
|
477.60M
|
54.9
Composite
|
$4.69
|
Profitability
74.8
|
|
Shell Companies
|
475.72M
|
54.3
Composite
|
$11.45
|
Valuation
72.7
|
|
Biotechnology
|
474.87M
|
61.6
Composite
|
$9.06
|
Profitability
71.3
|
|
VSTM
Verastem, Inc.
Biotechnology
|
474.52M
|
54.9
Composite
|
$6.74
|
Profitability
64.4
|
|
Biotechnology
|
474.33M
|
54.5
Composite
|
$3.73
|
Profitability
69.3
|
|
Biotechnology
|
465.73M
|
48.0
Composite
|
$11.95
|
Health
54.0
|
|
Biotechnology
|
463.10M
|
49.9
Composite
|
$13.63
|
Growth
60.6
|
|
Biotechnology
|
457.52M
|
50.6
Composite
|
$3.61
|
Profitability
66.4
|
|
Biotechnology
|
457.21M
|
46.5
Composite
|
$11.27
|
Valuation
55.8
|
|
Biotechnology
|
449.80M
|
57.1
Composite
|
$2.11
|
Profitability
67.2
|
|
Biotechnology
|
442.90M
|
61.8
Composite
|
$26.68
|
Profitability
79.7
|
|
Biotechnology
|
431.10M
|
62.1
Composite
|
$4.16
|
Profitability
70.1
|
|
Biotechnology
|
427.20M
|
42.6
Composite
|
$13.28
|
Profitability
49.8
|
|
Biotechnology
|
425.02M
|
50.0
Composite
|
$7.25
|
Efficiency
55.9
|
|
PRTC
PureTech Health plc
Biotechnology
|
423.21M
|
43.9
Composite
|
$17.38
|
Health
50.8
|
|
Biotechnology
|
416.62M
|
54.3
Composite
|
$2.00
|
Profitability
76.8
|
|
Biotechnology
|
416.00M
|
51.9
Composite
|
$2.15
|
Growth
59.1
|
|
Biotechnology
|
415.44M
|
56.0
Composite
|
$6.75
|
Profitability
80.5
|
|
Biotechnology
|
414.97M
|
67.6
Composite
|
$35.37
|
Profitability
88.2
|
|
Biotechnology
|
414.37M
|
61.4
Composite
|
$13.77
|
Profitability
77.8
|
|
Biotechnology
|
405.81M
|
57.1
Composite
|
$7.24
|
Profitability
72.9
|
|
Biotechnology
|
402.11M
|
66.6
Composite
|
$8.91
|
Profitability
80.3
|
|
Shell Companies
|
400.70M
|
48.0
Composite
|
$11.16
|
Profitability
55.5
|
|
Shell Companies
|
398.89M
|
49.4
Composite
|
$10.88
|
Profitability
57.4
|
|
Biotechnology
|
396.53M
|
48.2
Composite
|
$4.81
|
Growth
65.6
|
|
Biotechnology
|
392.93M
|
59.8
Composite
|
$5.25
|
Efficiency
77.5
|
|
Shell Companies
|
389.92M
|
50.6
Composite
|
$10.80
|
Profitability
60.6
|
|
Shell Companies
|
386.33M
|
41.2
Composite
|
$10.81
|
Efficiency
53.2
|
|
Biotechnology
|
383.70M
|
59.6
Composite
|
$5.00
|
Profitability
75.1
|
|
Biotechnology
|
373.51M
|
52.0
Composite
|
$4.64
|
Profitability
63.1
|
|
Biotechnology
|
362.50M
|
54.1
Composite
|
$2.80
|
Efficiency
59.4
|
|
PALI
Palisade Bio, Inc.
Biotechnology
|
361.05M
|
53.2
Composite
|
$2.11
|
Growth
77.9
|
|
Biotechnology
|
358.14M
|
66.9
Composite
|
$11.57
|
Profitability
82.1
|
|
Biotechnology
|
354.91M
|
51.8
Composite
|
$14.71
|
Health
55.6
|
|
Biotechnology
|
352.87M
|
51.9
Composite
|
$6.07
|
Profitability
70.1
|
|
Biotechnology
|
347.66M
|
49.6
Composite
|
$2.47
|
Valuation
55.3
|
|
Biotechnology
|
346.78M
|
60.0
Composite
|
$4.51
|
Profitability
78.0
|
|
Shell Companies
|
345.25M
|
46.6
Composite
|
$11.00
|
Growth
81.7
|
|
Biotechnology
|
334.58M
|
56.9
Composite
|
$4.22
|
Profitability
74.2
|
|
Shell Companies
|
334.16M
|
51.9
Composite
|
$10.70
|
Profitability
57.3
|
|
Biotechnology
|
331.91M
|
42.8
Composite
|
$3.66
|
Valuation
52.5
|
|
Shell Companies
|
330.00M
|
50.9
Composite
|
$10.75
|
Profitability
58.6
|
|
OABI
OmniAb, Inc.
Biotechnology
|
324.74M
|
61.2
Composite
|
$3.08
|
Profitability
79.6
|
|
Shell Companies
|
323.84M
|
46.4
Composite
|
$10.65
|
Profitability
56.8
|
|
Biotechnology
|
321.59M
|
52.9
Composite
|
$1.10
|
Profitability
76.7
|
|
Shell Companies
|
320.49M
|
53.9
Composite
|
$10.73
|
Efficiency
77.7
|
|
Biotechnology
|
319.26M
|
47.9
Composite
|
$3.69
|
Valuation
63.4
|
|
Shell Companies
|
317.82M
|
44.1
Composite
|
$10.81
|
Growth
54.6
|
|
Shell Companies
|
315.73M
|
49.8
Composite
|
$10.71
|
Growth
55.2
|
|
Shell Companies
|
311.36M
|
51.2
Composite
|
$10.82
|
Profitability
62.0
|
|
GRAF
Graf Global Corp.
Shell Companies
|
310.21M
|
42.1
Composite
|
$10.82
|
Valuation
47.5
|
|
Shell Companies
|
308.64M
|
45.0
Composite
|
$10.79
|
Growth
62.2
|
|
Shell Companies
|
308.34M
|
46.7
Composite
|
$10.77
|
Growth
55.2
|
|
Biotechnology
|
305.72M
|
55.6
Composite
|
$1.63
|
Profitability
60.5
|
|
Biotechnology
|
302.80M
|
53.0
Composite
|
$3.90
|
Growth
61.0
|
|
IFRX
InflaRx N.V.
Biotechnology
|
302.69M
|
45.0
Composite
|
$1.84
|
Valuation
59.1
|
|
Biotechnology
|
295.28M
|
41.2
Composite
|
$8.85
|
Valuation
52.3
|
|
Biotechnology
|
294.96M
|
49.8
Composite
|
$0.18
|
Growth
60.1
|
|
Biotechnology
|
291.81M
|
47.6
Composite
|
$4.17
|
Efficiency
66.2
|
|
MGNX
MacroGenics, Inc.
Biotechnology
|
290.50M
|
51.5
Composite
|
$4.04
|
Profitability
62.6
|
|
Biotechnology
|
287.79M
|
39.2
Composite
|
$3.45
|
Efficiency
57.5
|
|
Biotechnology
|
287.25M
|
49.8
Composite
|
$14.36
|
Health
72.9
|
|
Shell Companies
|
286.67M
|
45.1
Composite
|
$11.05
|
Growth
57.5
|
|
Shell Companies
|
282.56M
|
48.3
Composite
|
$10.87
|
Profitability
55.7
|
|
Shell Companies
|
281.87M
|
47.4
Composite
|
$10.63
|
Growth
56.9
|
|
Biotechnology
|
277.44M
|
47.3
Composite
|
$1.18
|
Valuation
70.7
|
|
SBXD
SilverBox Corp IV
Shell Companies
|
277.20M
|
47.3
Composite
|
$10.82
|
Profitability
56.1
|
|
Biotechnology
|
277.20M
|
55.1
Composite
|
$2.10
|
Growth
66.3
|
|
Shell Companies
|
274.56M
|
40.5
Composite
|
$10.69
|
Profitability
50.9
|
|
Shell Companies
|
273.99M
|
54.0
Composite
|
$9.52
|
Profitability
68.5
|
|
SRZN
Surrozen, Inc.
Biotechnology
|
272.84M
|
44.4
Composite
|
$25.62
|
Profitability
52.5
|
|
Shell Companies
|
272.08M
|
48.1
Composite
|
$10.67
|
Efficiency
56.3
|
|
Shell Companies
|
271.94M
|
44.4
Composite
|
$10.52
|
Profitability
53.8
|
|
Shell Companies
|
271.31M
|
43.4
Composite
|
$11.60
|
Growth
59.9
|
|
Shell Companies
|
270.00M
|
50.3
Composite
|
$10.81
|
Growth
68.5
|
|
Shell Companies
|
269.37M
|
43.3
Composite
|
$10.68
|
Growth
66.2
|
|
Biotechnology
|
266.65M
|
43.4
Composite
|
$6.87
|
Valuation
59.0
|
|
Shell Companies
|
262.79M
|
49.5
Composite
|
$10.74
|
Health
59.5
|
|
Shell Companies
|
259.26M
|
57.1
Composite
|
$7.68
|
Growth
82.2
|
|
Shell Companies
|
258.29M
|
50.6
Composite
|
$10.72
|
Growth
54.9
|
|
Shell Companies
|
257.22M
|
47.4
Composite
|
$10.57
|
Growth
55.7
|
|
ACIU
AC Immune SA
Biotechnology
|
256.40M
|
47.0
Composite
|
$2.36
|
Profitability
55.7
|
|
ADAG
Adagene Inc.
Biotechnology
|
254.38M
|
53.8
Composite
|
$4.11
|
Profitability
66.4
|
|
Biotechnology
|
251.43M
|
52.9
Composite
|
$1.27
|
Profitability
66.1
|
|
Biotechnology
|
250.21M
|
65.8
Composite
|
$3.34
|
Profitability
79.3
|
|
Biotechnology
|
249.60M
|
60.3
Composite
|
$88.00
|
Efficiency
78.0
|
|
Shell Companies
|
247.02M
|
50.1
Composite
|
$11.11
|
Growth
58.5
|
|
NKTX
Nkarta, Inc.
Biotechnology
|
241.82M
|
59.1
Composite
|
$2.41
|
Profitability
72.2
|
|
Biotechnology
|
241.45M
|
57.5
Composite
|
$0.90
|
Profitability
72.9
|
|
Biotechnology
|
239.21M
|
61.3
Composite
|
$3.89
|
Profitability
81.0
|
|
IVVD
Invivyd, Inc.
Biotechnology
|
236.78M
|
63.8
Composite
|
$0.74
|
Profitability
78.2
|
|
Biotechnology
|
236.35M
|
54.5
Composite
|
$7.49
|
Profitability
66.3
|
|
Shell Companies
|
235.68M
|
51.5
Composite
|
$10.92
|
Growth
72.8
|
|
CLLS
Cellectis S.A.
Biotechnology
|
233.80M
|
55.8
Composite
|
$2.83
|
Profitability
72.3
|
|
CGEN
Compugen Ltd.
Biotechnology
|
233.62M
|
65.1
Composite
|
$2.41
|
Profitability
79.7
|
|
CDXS
Codexis, Inc.
Biotechnology
|
232.70M
|
59.7
Composite
|
$1.47
|
Profitability
74.1
|
|
Biotechnology
|
232.34M
|
47.5
Composite
|
$4.24
|
Valuation
58.1
|
|
Biotechnology
|
231.16M
|
52.1
Composite
|
$2.12
|
Profitability
72.4
|
|
Biotechnology
|
231.00M
|
54.8
Composite
|
$4.12
|
Profitability
73.4
|
|
Biotechnology
|
225.36M
|
54.4
Composite
|
$4.24
|
Profitability
60.0
|
|
Biotechnology
|
225.23M
|
53.5
Composite
|
$11.15
|
Efficiency
79.4
|
|
Biotechnology
|
222.35M
|
52.3
Composite
|
$3.27
|
Profitability
66.8
|
|
Biotechnology
|
220.83M
|
61.3
Composite
|
$12.34
|
Profitability
78.8
|
|
Biotechnology
|
219.43M
|
43.2
Composite
|
$4.27
|
Profitability
55.2
|
|
QTTB
Q32 Bio Inc.
Biotechnology
|
213.48M
|
57.9
Composite
|
$15.60
|
Profitability
74.8
|
|
Shell Companies
|
212.80M
|
45.3
Composite
|
$10.85
|
Growth
58.6
|
|
KRRO
Korro Bio, Inc.
Biotechnology
|
206.24M
|
51.2
Composite
|
$13.25
|
Profitability
61.7
|
|
Biotechnology
|
203.72M
|
55.2
Composite
|
$12.03
|
Profitability
70.8
|
|
Biotechnology
|
203.51M
|
41.5
Composite
|
$7.41
|
Valuation
57.5
|
|
Biotechnology
|
203.05M
|
41.7
Composite
|
$1.02
|
Growth
63.2
|
|
IMUX
Immunic, Inc.
Biotechnology
|
201.33M
|
57.9
Composite
|
$14.30
|
Growth
64.8
|
|
THAR
Tharimmune, Inc.
Biotechnology
|
198.86M
|
51.2
Composite
|
$3.51
|
Profitability
56.3
|
|
Biotechnology
|
195.01M
|
47.3
Composite
|
$2.44
|
Health
54.6
|
|
Biotechnology
|
192.41M
|
55.1
Composite
|
$1.65
|
Profitability
65.7
|
|
Biotechnology
|
191.00M
|
76.1
Composite
|
$2.46
|
Profitability
85.0
|
|
MDWD
MediWound Ltd.
Biotechnology
|
189.06M
|
53.4
Composite
|
$14.39
|
Profitability
74.2
|
|
HUMA
Humacyte, Inc.
Biotechnology
|
188.83M
|
47.4
Composite
|
$0.72
|
Health
56.6
|
|
Biotechnology
|
187.15M
|
59.8
Composite
|
$2.11
|
Profitability
78.5
|
|
Shell Companies
|
186.47M
|
51.0
Composite
|
$11.34
|
Growth
85.3
|
|
ACOG
Alpha Cognition Inc.
Biotechnology
|
185.52M
|
56.2
Composite
|
$9.13
|
Profitability
79.8
|
|
Biotechnology
|
184.99M
|
52.3
Composite
|
$5.36
|
Profitability
59.8
|
|
Biotechnology
|
184.45M
|
49.9
Composite
|
$0.73
|
Growth
59.2
|
|
ALEC
Alector, Inc.
Biotechnology
|
181.53M
|
45.7
Composite
|
$1.78
|
Valuation
55.8
|
|
Biotechnology
|
180.16M
|
56.7
Composite
|
$4.14
|
Profitability
72.5
|
|
Biotechnology
|
179.00M
|
60.0
Composite
|
$10.17
|
Profitability
71.1
|
|
Biotechnology
|
178.80M
|
56.7
Composite
|
$1.88
|
Profitability
72.0
|
|
Biotechnology
|
178.23M
|
51.2
Composite
|
$1.22
|
Health
62.0
|
|
Biotechnology
|
177.31M
|
37.3
Composite
|
$4.71
|
Valuation
55.9
|
|
Biotechnology
|
171.07M
|
59.2
Composite
|
$4.30
|
Profitability
78.6
|
|
IPHA
Innate Pharma S.A.
Biotechnology
|
170.75M
|
40.7
Composite
|
$1.73
|
Profitability
46.4
|
|
Shell Companies
|
169.56M
|
41.2
Composite
|
$10.68
|
Growth
52.4
|
|
Biotechnology
|
167.48M
|
49.9
Composite
|
$2.21
|
Valuation
59.3
|
|
PYXS
Pyxis Oncology, Inc.
Biotechnology
|
167.26M
|
48.8
Composite
|
$3.73
|
Health
56.6
|
|
Biotechnology
|
166.75M
|
54.3
Composite
|
$5.93
|
Efficiency
63.3
|
|
ADCT
ADC Therapeutics SA
Biotechnology
|
165.35M
|
50.3
Composite
|
$1.13
|
Profitability
74.6
|
|
Biotechnology
|
161.63M
|
40.0
Composite
|
$1.00
|
Growth
48.9
|
|
PEPG
PepGen Inc.
Biotechnology
|
159.09M
|
55.8
Composite
|
$2.85
|
Profitability
64.5
|
|
Biotechnology
|
149.26M
|
49.6
Composite
|
$4.05
|
Profitability
65.5
|
|
Biotechnology
|
149.02M
|
53.8
Composite
|
$2.13
|
Profitability
67.2
|
|
Biotechnology
|
148.32M
|
49.6
Composite
|
$13.89
|
Health
57.8
|
|
Biotechnology
|
145.40M
|
57.8
Composite
|
$29.08
|
Profitability
77.0
|
|
CBUS
Cibus, Inc.
Biotechnology
|
145.00M
|
58.4
Composite
|
$1.81
|
Health
63.6
|
|
Biotechnology
|
142.00M
|
49.6
Composite
|
$3.58
|
Profitability
68.8
|
|
Biotechnology
|
140.44M
|
47.0
Composite
|
$5.07
|
Profitability
51.2
|
|
Biotechnology
|
138.74M
|
53.4
Composite
|
$1.55
|
Profitability
66.2
|
|
Biotechnology
|
137.06M
|
49.7
Composite
|
$46.87
|
Profitability
55.8
|
|
Biotechnology
|
135.10M
|
53.7
Composite
|
$27.12
|
Growth
77.2
|
|
AGEN
Agenus Inc.
Biotechnology
|
134.92M
|
50.9
Composite
|
$6.96
|
Profitability
75.6
|
|
VANI
Vivani Medical, Inc.
Biotechnology
|
134.53M
|
53.8
Composite
|
$1.41
|
Health
60.8
|
|
Biotechnology
|
132.78M
|
64.0
Composite
|
$0.55
|
Profitability
80.3
|
|
GNLX
Genelux Corporation
Biotechnology
|
132.34M
|
48.7
Composite
|
$2.66
|
Valuation
58.1
|
|
ENGN
enGene Holdings Inc.
Biotechnology
|
128.62M
|
56.9
Composite
|
$1.80
|
Profitability
72.5
|
|
Biotechnology
|
127.97M
|
51.9
Composite
|
$14.71
|
Growth
74.7
|
|
GUTS
Fractyl Health, Inc.
Biotechnology
|
125.57M
|
46.9
Composite
|
$0.70
|
Valuation
62.6
|
|
Biotechnology
|
123.38M
|
52.5
Composite
|
$4.81
|
Health
61.7
|
|
Biotechnology
|
122.75M
|
60.1
Composite
|
$1.26
|
Valuation
67.5
|
|
SEER
Seer, Inc.
Biotechnology
|
120.96M
|
57.0
Composite
|
$2.17
|
Profitability
69.9
|
|
Shell Companies
|
120.64M
|
50.9
Composite
|
$11.95
|
Health
58.7
|
|
Biotechnology
|
118.92M
|
50.1
Composite
|
$2.08
|
Profitability
70.0
|
|
Shell Companies
|
115.36M
|
39.0
Composite
|
$10.91
|
Growth
53.7
|
|
Biotechnology
|
114.24M
|
68.5
Composite
|
$2.65
|
Profitability
83.8
|
|
Biotechnology
|
112.18M
|
59.0
Composite
|
$5.08
|
Profitability
65.9
|
|
Biotechnology
|
109.80M
|
46.7
Composite
|
$0.80
|
Profitability
65.7
|
|
Shell Companies
|
109.67M
|
43.6
Composite
|
$17.11
|
Profitability
59.9
|
|
Biotechnology
|
109.60M
|
50.5
Composite
|
$3.42
|
Efficiency
52.9
|
|
Biotechnology
|
109.30M
|
66.6
Composite
|
$2.67
|
Profitability
75.6
|
|
Biotechnology
|
109.08M
|
57.3
Composite
|
$7.90
|
Profitability
78.9
|
|
Biotechnology
|
107.73M
|
61.5
Composite
|
$1.95
|
Profitability
80.5
|
|
Shell Companies
|
105.12M
|
42.3
Composite
|
$11.68
|
Valuation
60.2
|
|
PYPD
PolyPid Ltd.
Biotechnology
|
103.92M
|
54.4
Composite
|
$4.84
|
Valuation
60.2
|
|
ICCC
ImmuCell Corporation
Biotechnology
|
103.63M
|
68.5
Composite
|
$11.00
|
Profitability
80.3
|
|
FGMC
FG Merger II Corp.
Shell Companies
|
102.96M
|
54.1
Composite
|
$4.27
|
Efficiency
94.2
|
|
Shell Companies
|
100.29M
|
60.7
Composite
|
$10.69
|
Health
67.8
|
|
Biotechnology
|
97.90M
|
41.2
Composite
|
$0.67
|
Valuation
62.1
|
|
Biotechnology
|
97.55M
|
52.8
Composite
|
$1.08
|
Growth
61.4
|
|
Biotechnology
|
97.50M
|
57.1
Composite
|
$4.45
|
Profitability
73.5
|
|
ACET
Adicet Bio, Inc.
Biotechnology
|
93.88M
|
51.5
Composite
|
$7.98
|
Profitability
70.5
|
|
BMEA
Biomea Fusion, Inc.
Biotechnology
|
93.27M
|
55.0
Composite
|
$1.26
|
Profitability
66.3
|
|
Biotechnology
|
92.83M
|
45.3
Composite
|
$0.82
|
Efficiency
98.6
|
|
Shell Companies
|
92.22M
|
38.6
Composite
|
$12.94
|
Valuation
50.7
|
|
Biotechnology
|
90.25M
|
47.1
Composite
|
$0.99
|
Efficiency
54.4
|
|
Shell Companies
|
89.92M
|
46.8
Composite
|
$10.94
|
Growth
55.4
|
|
Shell Companies
|
89.70M
|
46.7
Composite
|
$11.80
|
Growth
53.5
|
|
Biotechnology
|
89.61M
|
47.4
Composite
|
$8.45
|
Profitability
66.9
|
|
Biotechnology
|
89.30M
|
55.2
Composite
|
$3.98
|
Efficiency
76.3
|
|
NRXS
Neuraxis, Inc.
Biotechnology
|
89.29M
|
60.7
Composite
|
$7.09
|
Profitability
72.7
|
|
Biotechnology
|
88.77M
|
55.0
Composite
|
$1.42
|
Growth
77.5
|
|
OKYO
OKYO Pharma Limited
Biotechnology
|
88.17M
|
43.5
Composite
|
$1.49
|
Profitability
68.1
|
|
Biotechnology
|
87.74M
|
56.1
Composite
|
$1.73
|
Profitability
70.7
|
|
Biotechnology
|
87.34M
|
57.8
Composite
|
$1.16
|
Growth
88.7
|
|
GOSS
Gossamer Bio, Inc.
Biotechnology
|
85.55M
|
50.5
Composite
|
$0.18
|
Profitability
62.8
|
|
Shell Companies
|
84.88M
|
49.2
Composite
|
$11.49
|
Valuation
56.9
|
|
Shell Companies
|
84.69M
|
42.9
Composite
|
$11.05
|
Health
47.6
|
|
RLYB
Rallybio Corporation
Biotechnology
|
83.87M
|
51.3
Composite
|
$16.16
|
Valuation
56.2
|
|
ENTX
Entera Bio Ltd.
Biotechnology
|
83.70M
|
47.6
Composite
|
$2.87
|
Efficiency
58.3
|
|
ANVS
Annovis Bio, Inc.
Biotechnology
|
82.96M
|
52.4
Composite
|
$1.88
|
Health
59.9
|
|
Biotechnology
|
82.34M
|
49.3
Composite
|
$0.80
|
Efficiency
62.6
|
|
Biotechnology
|
81.11M
|
55.5
Composite
|
$0.49
|
Profitability
70.9
|
|
Biotechnology
|
80.68M
|
57.3
Composite
|
$5.19
|
Profitability
84.4
|
|
Shell Companies
|
78.77M
|
34.2
Composite
|
$13.40
|
Health
49.7
|
|
Biotechnology
|
77.63M
|
48.3
Composite
|
$1.82
|
Growth
53.8
|
|
Biotechnology
|
76.61M
|
44.7
Composite
|
$1.60
|
Efficiency
88.7
|
|
IBIO
iBio, Inc.
Biotechnology
|
75.01M
|
49.4
Composite
|
$1.41
|
Growth
67.4
|
|
EURKU
Eureka Acquisition Corp
Shell Companies
|
72.60M
|
46.8
Composite
|
$11.64
|
Valuation
56.9
|
|
Biotechnology
|
72.19M
|
49.2
Composite
|
$0.07
|
Profitability
56.7
|
|
Biotechnology
|
71.98M
|
66.1
Composite
|
$19.88
|
Profitability
76.6
|
|
Shell Companies
|
69.82M
|
40.5
Composite
|
$10.94
|
Valuation
76.7
|
|
XBIT
XBiotech Inc.
Biotechnology
|
69.82M
|
50.9
Composite
|
$2.27
|
Profitability
72.5
|
|
Biotechnology
|
69.60M
|
57.4
Composite
|
$1.36
|
Profitability
68.2
|
|
Biotechnology
|
69.45M
|
53.2
Composite
|
$16.40
|
Profitability
61.3
|
|
Biotechnology
|
69.44M
|
49.7
Composite
|
$1.05
|
Valuation
55.1
|
|
Biotechnology
|
69.24M
|
54.8
Composite
|
$0.79
|
Growth
68.5
|
|
MNOV
MediciNova, Inc.
Biotechnology
|
68.91M
|
52.9
Composite
|
$1.34
|
Profitability
66.3
|
|
Shell Companies
|
68.23M
|
40.4
Composite
|
$11.19
|
Efficiency
48.3
|
|
Shell Companies
|
67.95M
|
40.2
Composite
|
$11.90
|
Health
48.6
|
|
CING
Cingulate Inc.
Biotechnology
|
66.67M
|
57.0
Composite
|
$5.34
|
Profitability
68.3
|
|
Biotechnology
|
66.56M
|
44.2
Composite
|
$3.19
|
Health
50.5
|
|
Biotechnology
|
66.13M
|
57.3
Composite
|
$1.19
|
Profitability
66.2
|
|
Biotechnology
|
66.03M
|
55.0
Composite
|
$2.45
|
Health
65.0
|
|
Biotechnology
|
65.27M
|
51.8
Composite
|
$4.87
|
Valuation
63.3
|
|
IMMP
Immutep Limited
Biotechnology
|
62.90M
|
51.5
Composite
|
$0.39
|
Profitability
63.7
|
|
EDSA
Edesa Biotech, Inc.
Biotechnology
|
62.42M
|
56.5
Composite
|
$5.27
|
Profitability
71.8
|
|
BYSI
BeyondSpring, Inc.
Biotechnology
|
61.30M
|
50.8
Composite
|
$0.87
|
Profitability
74.8
|
|
EXOZ
eXoZymes, Inc.
Biotechnology
|
60.03M
|
50.3
Composite
|
$5.11
|
Efficiency
89.8
|
|
Shell Companies
|
58.49M
|
53.5
Composite
|
$11.10
|
Valuation
74.1
|
|
Biotechnology
|
57.25M
|
52.4
Composite
|
$1.15
|
Profitability
68.4
|
|
ATYR
aTyr Pharma, Inc.
Biotechnology
|
57.10M
|
45.8
Composite
|
$0.51
|
Efficiency
56.5
|
|
Biotechnology
|
57.09M
|
54.5
Composite
|
$10.95
|
Profitability
75.8
|
|
Shell Companies
|
56.29M
|
42.4
Composite
|
$11.19
|
Profitability
55.4
|
|
Biotechnology
|
56.21M
|
54.0
Composite
|
$0.52
|
Growth
69.6
|
|
Biotechnology
|
55.04M
|
61.0
Composite
|
$9.17
|
Profitability
77.1
|
|
BOLD
Boundless Bio, Inc.
Biotechnology
|
55.03M
|
52.7
Composite
|
$2.89
|
Profitability
69.3
|
|
Biotechnology
|
54.62M
|
51.9
Composite
|
$0.48
|
Health
55.6
|
|
IBAC
IB Acquisition Corp.
Shell Companies
|
54.04M
|
39.3
Composite
|
$10.82
|
Health
55.6
|
|
Biotechnology
|
53.86M
|
48.6
Composite
|
$7.29
|
Health
53.5
|
|
TIL
Instil Bio, Inc.
Biotechnology
|
52.53M
|
54.9
Composite
|
$7.41
|
Profitability
73.2
|
|
Biotechnology
|
51.75M
|
48.6
Composite
|
$0.30
|
Efficiency
64.4
|
|
CRVO
CervoMed Inc.
Biotechnology
|
50.59M
|
54.0
Composite
|
$2.87
|
Profitability
75.4
|
|
Shell Companies
|
50.45M
|
24.2
Composite
|
$11.93
|
Efficiency
39.6
|
|
Shell Companies
|
50.26M
|
53.2
Composite
|
$11.78
|
Valuation
64.4
|
|
ATHA
Athira Pharma, Inc.
Biotechnology
|
50.13M
|
54.2
Composite
|
$7.66
|
Profitability
68.8
|
|
Biotechnology
|
48.79M
|
44.4
Composite
|
$0.43
|
Growth
50.2
|
|
INMB
INmune Bio Inc.
Biotechnology
|
47.59M
|
48.8
Composite
|
$2.08
|
Efficiency
60.0
|
|
MGX
Metagenomi, Inc.
Biotechnology
|
47.44M
|
47.5
Composite
|
$1.23
|
Profitability
57.9
|
|
Biotechnology
|
47.42M
|
53.4
Composite
|
$1.80
|
Profitability
73.2
|
|
Shell Companies
|
46.89M
|
40.9
Composite
|
$10.94
|
Profitability
51.3
|
|
Shell Companies
|
45.15M
|
33.5
Composite
|
$11.57
|
Health
53.5
|
|
VERU
Veru Inc.
Biotechnology
|
45.10M
|
57.3
Composite
|
$2.33
|
Profitability
73.0
|
|
Shell Companies
|
44.86M
|
48.5
Composite
|
$11.74
|
Growth
61.1
|
|
Biotechnology
|
43.94M
|
50.8
Composite
|
$0.78
|
Profitability
58.8
|
|
Shell Companies
|
43.64M
|
41.0
Composite
|
$12.20
|
Valuation
47.3
|
|
LTRN
Lantern Pharma Inc.
Biotechnology
|
42.74M
|
53.2
Composite
|
$2.86
|
Profitability
61.3
|
|
Biotechnology
|
41.89M
|
49.2
Composite
|
$5.59
|
Profitability
62.2
|
|
Shell Companies
|
41.47M
|
50.5
Composite
|
$11.24
|
Valuation
58.7
|
|
APLM
Apollomics Inc.
Biotechnology
|
41.29M
|
45.2
Composite
|
$16.90
|
Profitability
62.5
|
|
Biotechnology
|
40.90M
|
45.6
Composite
|
$0.72
|
Profitability
65.2
|
|
Shell Companies
|
40.81M
|
44.1
Composite
|
$12.20
|
Valuation
53.5
|
|
RNXT
RenovoRx, Inc.
Biotechnology
|
40.59M
|
58.2
Composite
|
$1.12
|
Profitability
70.3
|
|
Biotechnology
|
39.71M
|
55.8
Composite
|
$2.13
|
Profitability
74.2
|
|
Shell Companies
|
39.33M
|
29.6
Composite
|
$12.55
|
Growth
36.5
|
|
Biotechnology
|
38.99M
|
51.0
Composite
|
$1.00
|
Profitability
66.4
|
|
Shell Companies
|
38.74M
|
55.2
Composite
|
$11.06
|
Valuation
59.6
|
|
Shell Companies
|
38.13M
|
26.9
Composite
|
$13.27
|
Profitability
37.3
|
|
NTRB
Nutriband Inc.
Biotechnology
|
37.56M
|
48.8
Composite
|
$3.11
|
Profitability
66.8
|
|
Biotechnology
|
37.51M
|
58.3
Composite
|
$1.30
|
Growth
73.6
|
|
Shell Companies
|
37.05M
|
40.3
Composite
|
$13.45
|
Valuation
66.1
|
|
SNPX
Synaptogenix, Inc.
Biotechnology
|
36.76M
|
0.0
Composite
|
$24.55
|
No pillar score
-
|
|
ABVC
ABVC Biopharma, Inc.
Biotechnology
|
36.64M
|
53.5
Composite
|
$1.02
|
Profitability
83.8
|
|
NNVC
NanoViricides, Inc.
Biotechnology
|
33.60M
|
55.1
Composite
|
$1.42
|
Efficiency
97.5
|
|
Shell Companies
|
33.24M
|
49.2
Composite
|
$12.14
|
Valuation
73.3
|
|
Shell Companies
|
32.14M
|
44.8
Composite
|
$6.31
|
Valuation
54.9
|
|
Biotechnology
|
31.75M
|
42.5
Composite
|
$3.64
|
Growth
65.6
|
|
Biotechnology
|
31.14M
|
41.4
Composite
|
$0.35
|
Efficiency
63.2
|
|
Biotechnology
|
30.43M
|
44.7
Composite
|
$0.80
|
Valuation
62.9
|
|
Biotechnology
|
30.40M
|
50.9
Composite
|
$1.40
|
Efficiency
63.6
|
|
Biotechnology
|
30.00M
|
48.8
Composite
|
$2.40
|
Valuation
60.9
|
|
Biotechnology
|
29.43M
|
51.1
Composite
|
$1.10
|
Growth
74.6
|
|
Biotechnology
|
29.20M
|
48.5
Composite
|
$1.06
|
Valuation
58.2
|
|
Shell Companies
|
29.15M
|
30.5
Composite
|
$7.33
|
Valuation
49.7
|
|
FGEN
FibroGen, Inc
Biotechnology
|
27.90M
|
56.5
Composite
|
$7.21
|
Profitability
69.5
|
|
IGC
IGC Pharma, Inc.
Biotechnology
|
27.90M
|
52.1
Composite
|
$0.26
|
Profitability
70.5
|
|
Biotechnology
|
27.53M
|
53.5
Composite
|
$3.86
|
Profitability
69.0
|
|
Shell Companies
|
27.52M
|
38.5
Composite
|
$9.19
|
Efficiency
53.6
|
|
PLRZ
Polyrizon Ltd.
Biotechnology
|
26.88M
|
52.7
Composite
|
$11.59
|
Profitability
68.3
|
|
EVAX
Evaxion Biotech A/S
Biotechnology
|
26.69M
|
57.5
Composite
|
$3.10
|
Profitability
75.0
|
|
Biotechnology
|
26.51M
|
55.9
Composite
|
$1.12
|
Profitability
72.0
|
|
NKGN
NKGen Biotech, Inc.
Biotechnology
|
26.12M
|
44.4
Composite
|
$0.01
|
Valuation
65.6
|
|
Biotechnology
|
26.06M
|
50.7
Composite
|
$0.60
|
Profitability
72.2
|
|
Biotechnology
|
25.90M
|
42.5
Composite
|
$0.90
|
Efficiency
54.5
|
|
MEIP
MEI Pharma, Inc.
Biotechnology
|
25.70M
|
0.0
Composite
|
$3.07
|
No pillar score
-
|
|
Biotechnology
|
25.45M
|
37.8
Composite
|
$0.50
|
Profitability
50.9
|
|
Shell Companies
|
25.36M
|
50.9
Composite
|
$10.59
|
Health
73.0
|
|
Shell Companies
|
25.22M
|
46.6
Composite
|
$11.98
|
Valuation
53.8
|
|
KALA
KALA BIO, Inc.
Biotechnology
|
25.10M
|
42.6
Composite
|
$0.75
|
Valuation
55.7
|
|
Biotechnology
|
24.63M
|
44.0
Composite
|
$0.52
|
Valuation
56.4
|
|
Shell Companies
|
23.82M
|
31.9
Composite
|
$0.49
|
Valuation
58.2
|
|
Biotechnology
|
23.62M
|
47.8
Composite
|
$6.47
|
Profitability
63.5
|
|
Biotechnology
|
23.59M
|
51.2
Composite
|
$1.72
|
Growth
56.5
|
|
Shell Companies
|
23.33M
|
24.1
Composite
|
$12.50
|
Valuation
43.3
|
|
Shell Companies
|
23.18M
|
47.7
Composite
|
$10.73
|
Valuation
55.9
|
|
Biotechnology
|
23.04M
|
42.3
Composite
|
$7.00
|
Growth
52.0
|
|
Shell Companies
|
22.51M
|
37.5
Composite
|
$0.05
|
Profitability
51.4
|
|
Biotechnology
|
22.41M
|
49.6
Composite
|
$27.86
|
Efficiency
57.9
|
|
Biotechnology
|
22.14M
|
45.0
Composite
|
$2.57
|
Health
56.8
|
|
CELU
Celularity Inc.
Biotechnology
|
21.65M
|
43.1
Composite
|
$0.70
|
Profitability
65.7
|
|
LGVN
Longeveron Inc.
Biotechnology
|
20.55M
|
53.2
Composite
|
$0.77
|
Profitability
61.0
|
|
LPCN
Lipocine Inc.
Biotechnology
|
20.36M
|
46.5
Composite
|
$2.13
|
Profitability
53.5
|
|
Biotechnology
|
20.32M
|
48.0
Composite
|
$2.36
|
Valuation
57.5
|
|
Biotechnology
|
19.70M
|
54.6
Composite
|
$3.28
|
Profitability
63.7
|
|
PLUR
Pluri Inc.
Biotechnology
|
19.21M
|
42.3
Composite
|
$1.82
|
Efficiency
62.9
|
|
Biotechnology
|
19.09M
|
51.7
Composite
|
$1.39
|
Health
59.5
|
|
Biotechnology
|
18.97M
|
56.5
Composite
|
$3.82
|
Profitability
79.6
|
|
Biotechnology
|
18.45M
|
50.0
Composite
|
$7.77
|
Profitability
75.1
|
|
Biotechnology
|
18.39M
|
47.2
Composite
|
$0.40
|
Efficiency
62.9
|
|
Biotechnology
|
18.14M
|
45.8
Composite
|
$0.82
|
Valuation
53.8
|
|
Biotechnology
|
17.10M
|
52.5
Composite
|
$30.20
|
Health
58.8
|
|
BIVI
BioVie Inc.
Biotechnology
|
16.89M
|
51.8
Composite
|
$1.00
|
Profitability
71.4
|
|
Biotechnology
|
16.71M
|
55.8
Composite
|
$0.51
|
Growth
71.5
|
|
Biotechnology
|
16.67M
|
59.8
Composite
|
$3.57
|
Profitability
70.8
|
|
GTBP
GT Biopharma, Inc.
Biotechnology
|
16.13M
|
57.2
Composite
|
$0.32
|
Profitability
67.3
|
|
Biotechnology
|
15.40M
|
50.8
Composite
|
$0.68
|
Profitability
59.3
|
|
MLEC
Moolec Science SA
Biotechnology
|
15.25M
|
47.9
Composite
|
$7.19
|
Profitability
69.7
|
|
Biotechnology
|
15.20M
|
40.9
Composite
|
$5.27
|
Growth
49.9
|
|
CALC
CalciMedica, Inc.
Biotechnology
|
15.01M
|
48.4
Composite
|
$0.69
|
Profitability
57.5
|
|
PASG
Passage Bio, Inc.
Biotechnology
|
14.79M
|
54.8
Composite
|
$4.40
|
Profitability
66.0
|
|
Biotechnology
|
14.62M
|
44.3
Composite
|
$0.92
|
Valuation
52.6
|
|
Biotechnology
|
14.41M
|
53.3
Composite
|
$0.71
|
Health
64.5
|
|
Biotechnology
|
13.93M
|
51.4
Composite
|
$1.06
|
Profitability
61.6
|
|
HOOK
HOOKIPA Pharma Inc.
Biotechnology
|
13.86M
|
57.0
Composite
|
$1.15
|
Profitability
76.2
|
|
INAB
IN8bio, Inc.
Biotechnology
|
13.79M
|
58.4
Composite
|
$0.98
|
Profitability
71.0
|
|
Biotechnology
|
13.27M
|
54.7
Composite
|
$4.16
|
Profitability
64.3
|
|
AEON
AEON Biopharma, Inc.
Biotechnology
|
13.22M
|
43.4
Composite
|
$0.28
|
Profitability
62.2
|
|
Biotechnology
|
13.18M
|
47.1
Composite
|
$1.93
|
Profitability
64.2
|
|
Biotechnology
|
13.05M
|
57.5
Composite
|
$0.30
|
Profitability
74.6
|
|
BLRX
BioLineRx Ltd.
Biotechnology
|
13.05M
|
57.6
Composite
|
$2.71
|
Profitability
73.4
|
|
Biotechnology
|
13.02M
|
48.6
Composite
|
$0.41
|
Health
61.5
|
|
XCUR
Exicure, Inc.
Biotechnology
|
12.11M
|
40.9
Composite
|
$1.34
|
Profitability
57.1
|
|
Biotechnology
|
12.08M
|
52.8
Composite
|
$1.04
|
Valuation
59.3
|
|
RENB
Renovaro Inc.
Biotechnology
|
11.60M
|
0.0
Composite
|
$0.32
|
No pillar score
-
|
|
Biotechnology
|
11.60M
|
50.1
Composite
|
$0.82
|
Profitability
65.3
|
|
Biotechnology
|
11.30M
|
57.9
Composite
|
$2.64
|
Profitability
80.8
|
|
Biotechnology
|
11.18M
|
45.2
Composite
|
$3.47
|
Valuation
60.0
|
|
Biotechnology
|
10.76M
|
53.0
Composite
|
$0.22
|
Profitability
63.5
|
|
IMRN
Immuron Limited
Biotechnology
|
10.30M
|
48.9
Composite
|
$1.03
|
Profitability
68.6
|
|
TRAW
Traws Pharma, Inc.
Biotechnology
|
10.23M
|
50.9
Composite
|
$0.53
|
Profitability
74.7
|
|
BCDA
BioCardia, Inc.
Biotechnology
|
10.15M
|
38.3
Composite
|
$0.98
|
Valuation
47.2
|
|
CRIS
Curis, Inc.
Biotechnology
|
9.67M
|
48.9
Composite
|
$4.02
|
Health
62.6
|
|
Biotechnology
|
9.63M
|
38.0
Composite
|
$0.29
|
Valuation
48.5
|
|
Biotechnology
|
9.48M
|
51.0
Composite
|
$4.79
|
Health
63.3
|
|
Biotechnology
|
9.12M
|
44.0
Composite
|
$3.96
|
Profitability
52.7
|
|
Biotechnology
|
9.01M
|
61.0
Composite
|
$0.65
|
Profitability
69.8
|
|
MTVA
MetaVia Inc.
Biotechnology
|
8.93M
|
60.6
Composite
|
$1.49
|
Profitability
65.5
|
|
Biotechnology
|
8.80M
|
46.7
Composite
|
$0.20
|
Health
61.3
|
|
Biotechnology
|
8.63M
|
39.8
Composite
|
$1.95
|
Valuation
47.2
|
|
Biotechnology
|
8.61M
|
49.7
Composite
|
$0.79
|
Profitability
61.5
|
|
Biotechnology
|
8.51M
|
42.1
Composite
|
$0.08
|
Valuation
52.4
|
|
IMNN
Imunon, Inc.
Biotechnology
|
8.40M
|
52.6
Composite
|
$1.61
|
Profitability
65.1
|
|
SYBX
Synlogic, Inc.
Biotechnology
|
8.19M
|
47.0
Composite
|
$1.23
|
Valuation
52.8
|
|
KAPA
Kairos Pharma, Ltd.
Biotechnology
|
7.92M
|
59.5
Composite
|
$0.39
|
Efficiency
97.2
|
|
Biotechnology
|
7.92M
|
42.7
Composite
|
$1.17
|
Profitability
63.5
|
|
Biotechnology
|
7.77M
|
40.5
Composite
|
$5.38
|
Valuation
62.8
|
|
Biotechnology
|
7.65M
|
44.0
Composite
|
$4.05
|
Valuation
59.9
|
|
Biotechnology
|
7.56M
|
40.7
Composite
|
$3.44
|
Valuation
51.4
|
|
Biotechnology
|
7.50M
|
57.1
Composite
|
$0.59
|
Profitability
78.7
|
|
Biotechnology
|
7.34M
|
35.8
Composite
|
$5.80
|
Profitability
45.8
|
|
Biotechnology
|
7.04M
|
52.8
Composite
|
$0.43
|
Profitability
61.1
|
|
Biotechnology
|
6.92M
|
43.6
Composite
|
$4.21
|
Growth
59.7
|
|
PULM
Pulmatrix, Inc.
Biotechnology
|
6.57M
|
54.5
Composite
|
$1.66
|
Profitability
68.8
|
|
Biotechnology
|
6.52M
|
46.2
Composite
|
$2.94
|
Profitability
62.4
|
|
NXTC
NextCure, Inc.
Biotechnology
|
6.43M
|
55.4
Composite
|
$5.84
|
Profitability
70.8
|
|
Biotechnology
|
6.40M
|
47.7
Composite
|
$0.29
|
Valuation
62.5
|
|
Biotechnology
|
6.39M
|
49.7
Composite
|
$8.41
|
Profitability
59.7
|
|
Biotechnology
|
6.27M
|
56.9
Composite
|
$1.54
|
Profitability
70.3
|
|
PPBT
Purple Biotech Ltd.
Biotechnology
|
6.22M
|
57.4
Composite
|
$1.43
|
Profitability
77.1
|
|
Biotechnology
|
6.21M
|
65.9
Composite
|
$3.17
|
Profitability
80.7
|
|
Biotechnology
|
6.00M
|
45.9
Composite
|
$3.98
|
Growth
58.3
|
|
BCAB
BioAtla, Inc.
Biotechnology
|
5.96M
|
43.4
Composite
|
$3.46
|
Efficiency
57.5
|
|
GNPX
Genprex, Inc.
Biotechnology
|
5.88M
|
47.0
Composite
|
$4.27
|
Growth
67.4
|
|
Shell Companies
|
5.87M
|
48.6
Composite
|
$0.38
|
Growth
56.9
|
|
Biotechnology
|
5.68M
|
47.9
Composite
|
$1.79
|
Efficiency
66.4
|
|
MBIO
Mustang Bio, Inc.
Biotechnology
|
5.61M
|
53.9
Composite
|
$0.60
|
Profitability
76.5
|
|
HCWB
HCW Biologics Inc.
Biotechnology
|
5.54M
|
62.6
Composite
|
$3.41
|
Profitability
80.1
|
|
SNGX
Soligenix, Inc.
Biotechnology
|
5.50M
|
43.8
Composite
|
$0.39
|
Health
51.4
|
|
Biotechnology
|
5.42M
|
51.4
Composite
|
$2.57
|
Efficiency
93.6
|
|
Biotechnology
|
5.39M
|
57.8
Composite
|
$1.10
|
Profitability
72.0
|
|
Biotechnology
|
5.27M
|
46.0
Composite
|
$1.55
|
Profitability
61.3
|
|
Biotechnology
|
5.20M
|
45.0
Composite
|
$0.34
|
Valuation
61.8
|
|
NCNA
NuCana plc
Biotechnology
|
5.16M
|
64.8
Composite
|
$1.47
|
Efficiency
85.6
|
|
Biotechnology
|
5.07M
|
45.4
Composite
|
$2.98
|
Efficiency
59.0
|
|
Biotechnology
|
4.91M
|
49.3
Composite
|
$4.18
|
Profitability
58.9
|
|
Biotechnology
|
4.90M
|
48.0
Composite
|
$1.99
|
Efficiency
59.4
|
|
ELAB
PMGC Holdings Inc.
Biotechnology
|
4.82M
|
52.5
Composite
|
$0.92
|
Profitability
62.1
|
|
FBLG
FibroBiologics, Inc.
Biotechnology
|
4.65M
|
45.3
Composite
|
$0.98
|
Valuation
56.4
|
|
EVGN
Evogene Ltd.
Biotechnology
|
4.60M
|
51.7
Composite
|
$0.60
|
Profitability
74.8
|
|
Biotechnology
|
4.35M
|
46.6
Composite
|
$0.13
|
Profitability
63.0
|
|
ALZN
Alzamend Neuro, Inc.
Biotechnology
|
4.34M
|
53.2
Composite
|
$1.37
|
Efficiency
91.2
|
|
Biotechnology
|
4.17M
|
49.6
Composite
|
$0.08
|
Profitability
55.0
|
|
Biotechnology
|
4.15M
|
52.0
Composite
|
$1.12
|
Profitability
61.1
|
|
Biotechnology
|
4.07M
|
41.7
Composite
|
$0.52
|
Profitability
54.9
|
|
GOVX
GeoVax Labs, Inc.
Biotechnology
|
4.06M
|
40.3
Composite
|
$0.77
|
Valuation
46.7
|
|
Biotechnology
|
3.90M
|
48.3
Composite
|
$0.28
|
Profitability
53.0
|
|
Biotechnology
|
3.81M
|
48.8
Composite
|
$1.14
|
Growth
63.7
|
|
Biotechnology
|
3.75M
|
60.2
Composite
|
$0.60
|
Growth
68.8
|
|
Biotechnology
|
3.72M
|
58.7
Composite
|
$8.28
|
Efficiency
94.1
|
|
ONCO
Onconetix, Inc.
Biotechnology
|
3.64M
|
44.0
Composite
|
$0.89
|
Growth
55.4
|
|
Biotechnology
|
3.56M
|
52.5
Composite
|
$0.72
|
Health
59.7
|
|
Biotechnology
|
3.48M
|
45.8
Composite
|
$1.42
|
Efficiency
60.4
|
|
GRI
GRI Bio, Inc.
Biotechnology
|
3.15M
|
46.0
Composite
|
$1.47
|
Profitability
59.8
|
|
SPRC
SciSparc Ltd.
Biotechnology
|
3.12M
|
39.3
Composite
|
$6.93
|
Valuation
45.0
|
|
Biotechnology
|
3.08M
|
47.0
Composite
|
$1.63
|
Growth
57.5
|
|
Biotechnology
|
2.91M
|
45.2
Composite
|
$1.62
|
Health
54.4
|
|
PHGE
BiomX Inc.
Biotechnology
|
2.84M
|
44.0
Composite
|
$0.17
|
Profitability
62.7
|
|
VCNX
Vaccinex, Inc.
Biotechnology
|
2.81M
|
37.6
Composite
|
$0.99
|
Valuation
54.7
|
|
OGEN
Oragenics Inc.
Biotechnology
|
2.60M
|
60.1
Composite
|
$0.55
|
Profitability
71.6
|
|
AZTR
Azitra Inc
Biotechnology
|
2.41M
|
41.4
Composite
|
$0.14
|
Efficiency
56.4
|
|
Biotechnology
|
2.15M
|
44.1
Composite
|
$1.54
|
Health
56.6
|
|
Biotechnology
|
2.15M
|
48.1
Composite
|
$0.25
|
Valuation
55.2
|
|
Biotechnology
|
2.01M
|
40.4
Composite
|
$0.04
|
Valuation
43.3
|
|
Biotechnology
|
1.99M
|
46.2
Composite
|
$3.42
|
Profitability
65.6
|
|
Shell Companies
|
1.77M
|
56.1
Composite
|
$1.67
|
Profitability
58.1
|
|
JAGX
Jaguar Health, Inc.
Biotechnology
|
1.45M
|
57.6
Composite
|
$0.95
|
Profitability
78.8
|
|
Biotechnology
|
1.28M
|
53.5
Composite
|
$0.26
|
Profitability
66.2
|
|
Biotechnology
|
1.28M
|
42.1
Composite
|
$0.31
|
Valuation
52.0
|
|
Biotechnology
|
1.09M
|
41.5
Composite
|
$1.87
|
Valuation
56.5
|
|
Biotechnology
|
1.02M
|
54.8
Composite
|
$0.24
|
Profitability
74.2
|
|
Biotechnology
|
890,551
|
37.6
Composite
|
$0.12
|
Efficiency
43.2
|
|
Biotechnology
|
843,068
|
43.4
Composite
|
$0.34
|
Efficiency
58.8
|
|
Biotechnology
|
631,573
|
50.0
Composite
|
$0.01
|
Efficiency
92.6
|
|
Biotechnology
|
497,436
|
50.0
Composite
|
$2.13
|
Profitability
61.5
|
|
IOBT
IO Biotech, Inc.
Biotechnology
|
467,667
|
49.0
Composite
|
$0.01
|
Health
66.2
|
|
Biotechnology
|
441,572
|
47.9
Composite
|
$0.05
|
Growth
58.6
|
|
Biotechnology
|
337,087
|
34.5
Composite
|
$0.00
|
Profitability
37.3
|
|
Biotechnology
|
161,729
|
47.1
Composite
|
$0.00
|
Growth
58.4
|
|
Biotechnology
|
104,612
|
56.2
Composite
|
$0.00
|
Profitability
67.5
|
|
Biotechnology
|
92,946
|
38.6
Composite
|
$0.00
|
Profitability
46.3
|
|
VINC
Vincerx Pharma, Inc.
Biotechnology
|
65,428
|
41.9
Composite
|
$0.01
|
Efficiency
55.1
|
|
Shell Companies
|
16,591
|
37.0
Composite
|
$0.00
|
Efficiency
72.9
|
|
Biotechnology
|
10,732
|
45.1
Composite
|
$0.00
|
Profitability
50.8
|
|
ADTX
Aditxt, Inc.
Biotechnology
|
2,611
|
34.2
Composite
|
$0.00
|
Valuation
44.3
|
|
Biotechnology
|
940
|
40.1
Composite
|
$0.00
|
Efficiency
58.4
|
|
Biotechnology
|
124
|
32.5
Composite
|
$0.00
|
Valuation
40.8
|
|
ATNFW
180 Life Sciences Corp.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
TSVT
2seventy bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
CSLMF
6816
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
ETNB
89bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
47.4
Composite
|
$10.82
|
Health
73.0
|
|
Shell Companies
|
-
|
44.2
Composite
|
$10.66
|
Health
64.3
|
|
Biotechnology
|
-
|
58.4
Composite
|
-
|
Profitability
72.9
|
|
ABPWW
Abpro Holdings, Inc.
Biotechnology
|
-
|
44.3
Composite
|
$0.01
|
Profitability
47.7
|
|
SLRN
ACELYRIN, INC.
Biotechnology
|
-
|
38.7
Composite
|
-
|
Health
56.8
|
|
Biotechnology
|
-
|
62.1
Composite
|
-
|
Profitability
75.3
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
56.1
Composite
|
-
|
Profitability
72.9
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
AFMD
Affimed N.V.
Biotechnology
|
-
|
43.3
Composite
|
$0.18
|
Health
63.5
|
|
Shell Companies
|
-
|
50.5
Composite
|
$0.14
|
Health
53.7
|
|
Shell Companies
|
-
|
50.5
Composite
|
$11.69
|
Health
53.7
|
|
Shell Companies
|
-
|
49.1
Composite
|
-
|
Growth
100.0
|
|
Shell Companies
|
-
|
49.1
Composite
|
-
|
Growth
100.0
|
|
Shell Companies
|
-
|
38.4
Composite
|
$12.00
|
Profitability
48.2
|
|
Shell Companies
|
-
|
0.0
Composite
|
$19.26
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$18.15
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
29.4
Composite
|
$13.50
|
Health
45.4
|
|
ALDFU
Aldel Financial II Inc.
Shell Companies
|
-
|
52.2
Composite
|
$10.82
|
Growth
77.8
|
|
Shell Companies
|
-
|
52.6
Composite
|
$0.33
|
Growth
77.8
|
|
ALLK
Allakos Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
ALVR
AlloVir, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
54.2
Composite
|
$3.51
|
Efficiency
69.5
|
|
Shell Companies
|
-
|
49.1
Composite
|
-
|
Efficiency
62.6
|
|
Shell Companies
|
-
|
49.0
Composite
|
-
|
Efficiency
62.6
|
|
Shell Companies
|
-
|
47.6
Composite
|
-
|
Efficiency
62.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
27.8
Composite
|
-
|
Profitability
38.0
|
|
Shell Companies
|
-
|
31.4
Composite
|
$12.01
|
Profitability
41.6
|
|
Shell Companies
|
-
|
29.0
Composite
|
$4.50
|
Profitability
38.0
|
|
Shell Companies
|
-
|
44.2
Composite
|
$10.86
|
Growth
58.5
|
|
Biotechnology
|
-
|
48.9
Composite
|
$0.10
|
Profitability
56.3
|
|
Biotechnology
|
-
|
43.4
Composite
|
$1.71
|
Profitability
53.8
|
|
APXIU
APx Acquisition Corp. I
Shell Companies
|
-
|
30.1
Composite
|
-
|
Efficiency
48.6
|
|
Shell Companies
|
-
|
27.7
Composite
|
-
|
Efficiency
48.6
|
|
Shell Companies
|
-
|
26.2
Composite
|
$12.79
|
Health
30.2
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
29.0
Composite
|
-
|
Profitability
42.7
|
|
Shell Companies
|
-
|
25.1
Composite
|
-
|
Health
30.2
|
|
Shell Companies
|
-
|
29.0
Composite
|
-
|
Profitability
42.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
52.7
Composite
|
-
|
Health
68.8
|
|
Shell Companies
|
-
|
37.8
Composite
|
-
|
Health
43.7
|
|
Shell Companies
|
-
|
37.8
Composite
|
-
|
Health
43.7
|
|
BAYAU
Bayview Acquisition Corp
Shell Companies
|
-
|
40.2
Composite
|
$12.00
|
Health
54.1
|
|
BGNE
BeiGene, Ltd.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
34.0
Composite
|
-
|
Health
46.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
40.0
Composite
|
$0.03
|
Growth
60.2
|
|
Shell Companies
|
-
|
49.5
Composite
|
$12.00
|
Profitability
55.7
|
|
Shell Companies
|
-
|
64.0
Composite
|
$11.00
|
Growth
100.0
|
|
BLEU
bleuacacia ltd
Shell Companies
|
-
|
30.4
Composite
|
-
|
Efficiency
44.8
|
|
BLEUU
bleuacacia ltd
Shell Companies
|
-
|
30.4
Composite
|
-
|
Efficiency
44.8
|
|
BLEUW
bleuacacia ltd Warrants
Shell Companies
|
-
|
30.8
Composite
|
-
|
Efficiency
44.8
|
|
BLUE
bluebird bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
53.2
Composite
|
$11.03
|
Growth
58.4
|
|
Shell Companies
|
-
|
34.5
Composite
|
$0.00
|
Efficiency
72.9
|
|
BOWNU
Bowen Acquisition Corp
Shell Companies
|
-
|
35.2
Composite
|
-
|
Efficiency
50.6
|
|
Biotechnology
|
-
|
45.8
Composite
|
$0.00
|
Growth
62.9
|
|
Shell Companies
|
-
|
40.2
Composite
|
$12.00
|
Health
50.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.70
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
43.4
Composite
|
-
|
Health
52.6
|
|
Shell Companies
|
-
|
35.9
Composite
|
$14.39
|
Profitability
47.2
|
|
Shell Companies
|
-
|
35.9
Composite
|
$0.12
|
Profitability
47.2
|
|
Shell Companies
|
-
|
41.5
Composite
|
-
|
Growth
66.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
44.2
Composite
|
$0.01
|
Efficiency
66.4
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.69
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.75
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$180.56
|
No pillar score
-
|
|
Shell Companies
|
-
|
46.5
Composite
|
$11.17
|
Health
50.1
|
|
CELUW
Celularity Inc.
Biotechnology
|
-
|
44.0
Composite
|
$0.01
|
Profitability
66.6
|
|
Shell Companies
|
-
|
43.2
Composite
|
$10.91
|
Efficiency
59.2
|
|
Biotechnology
|
-
|
46.4
Composite
|
$0.00
|
Efficiency
92.6
|
|
Shell Companies
|
-
|
38.6
Composite
|
$11.28
|
Health
50.6
|
|
CFFSU
CF Acquisition Corp. VII
Shell Companies
|
-
|
38.6
Composite
|
$11.18
|
Health
50.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
35.7
Composite
|
$10.80
|
Growth
58.4
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
CMRX
Chimerix, Inc.
Biotechnology
|
-
|
48.7
Composite
|
-
|
Health
66.7
|
|
Shell Companies
|
-
|
52.5
Composite
|
$10.81
|
Profitability
60.1
|
|
Biotechnology
|
-
|
44.5
Composite
|
$221.38
|
Profitability
48.2
|
|
CINGW
Cingulate Inc. Warrants
Biotechnology
|
-
|
57.2
Composite
|
$0.02
|
Profitability
66.0
|
|
CLRCU
ClimateRock
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
CLRC
ClimateRock
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
CLRCW
ClimateRock Warrant
Shell Companies
|
-
|
0.0
Composite
|
$0.03
|
No pillar score
-
|
|
Shell Companies
|
-
|
57.4
Composite
|
$12.12
|
Health
67.8
|
|
Shell Companies
|
-
|
57.2
Composite
|
$0.16
|
Health
67.8
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
39.5
Composite
|
$0.01
|
Profitability
53.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
$2.72
|
No pillar score
-
|
|
CYBN
Cybin Inc.
Biotechnology
|
-
|
56.7
Composite
|
$7.61
|
Efficiency
73.4
|
|
Biotechnology
|
-
|
59.0
Composite
|
-
|
Profitability
80.8
|
|
Biotechnology
|
-
|
47.8
Composite
|
-
|
Profitability
61.9
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.43
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Shell Companies
|
-
|
32.7
Composite
|
$11.84
|
Efficiency
43.9
|
|
Biotechnology
|
-
|
52.0
Composite
|
$0.02
|
Profitability
69.4
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
26.2
Composite
|
-
|
Health
32.9
|
|
Shell Companies
|
-
|
26.2
Composite
|
-
|
Health
32.9
|
|
Shell Companies
|
-
|
26.2
Composite
|
-
|
Health
32.9
|
|
Shell Companies
|
-
|
18.8
Composite
|
-
|
Efficiency
32.9
|
|
Shell Companies
|
-
|
19.0
Composite
|
-
|
Efficiency
32.9
|
|
Shell Companies
|
-
|
38.3
Composite
|
-
|
Health
47.3
|
|
DUETU
DUET Acquisition Corp.
Shell Companies
|
-
|
38.3
Composite
|
-
|
Health
47.3
|
|
Shell Companies
|
-
|
38.3
Composite
|
-
|
Health
47.3
|
|
DYNXU
Dynamix Corporation
Shell Companies
|
-
|
0.0
Composite
|
$10.89
|
No pillar score
-
|
|
DYNX
Dynamix Corporation
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.78
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.00
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.80
|
No pillar score
-
|
|
Shell Companies
|
-
|
44.1
Composite
|
-
|
Health
51.9
|
|
Biotechnology
|
-
|
54.7
Composite
|
$0.32
|
Profitability
70.1
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
EPIX
ESSA Pharma Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
42.7
Composite
|
$0.06
|
Profitability
62.7
|
|
EYEN
Eyenovia, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
48.3
Composite
|
$10.83
|
Efficiency
60.8
|
|
FGMCU
FG Merger II Corp.
Shell Companies
|
-
|
53.3
Composite
|
$8.97
|
Efficiency
93.6
|
|
Shell Companies
|
-
|
29.6
Composite
|
$0.09
|
Health
44.1
|
|
Shell Companies
|
-
|
35.0
Composite
|
-
|
Health
52.5
|
|
Shell Companies
|
-
|
35.0
Composite
|
-
|
Health
52.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.05
|
No pillar score
-
|
|
Shell Companies
|
-
|
30.8
Composite
|
$11.01
|
Health
37.9
|
|
FICVW
Frontier Investment Corp
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
FHLTW
Future Health ESG Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
FHLTU
Future Health ESG Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
47.2
Composite
|
$10.67
|
Growth
55.6
|
|
Shell Companies
|
-
|
24.3
Composite
|
$12.00
|
Health
41.5
|
|
Shell Companies
|
-
|
25.3
Composite
|
$12.02
|
Health
41.5
|
|
Shell Companies
|
-
|
24.3
Composite
|
$0.03
|
Health
41.5
|
|
GBIO
Generation Bio Co.
Biotechnology
|
-
|
53.5
Composite
|
$5.34
|
Efficiency
66.5
|
|
GNFT
GENFIT S.A.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
GOVXW
GeoVax Labs, Inc.
Biotechnology
|
-
|
38.6
Composite
|
-
|
Profitability
44.0
|
|
Shell Companies
|
-
|
54.4
Composite
|
$9.94
|
Health
57.6
|
|
Shell Companies
|
-
|
37.5
Composite
|
$0.00
|
Health
64.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$10.82
|
No pillar score
-
|
|
Shell Companies
|
-
|
48.2
Composite
|
$11.00
|
Growth
89.5
|
|
Shell Companies
|
-
|
0.0
Composite
|
$6.56
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$6.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.04
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
GLYC
GlycoMimetics, Inc.
Biotechnology
|
-
|
48.3
Composite
|
-
|
Health
66.4
|
|
Shell Companies
|
-
|
31.2
Composite
|
$0.01
|
Profitability
42.8
|
|
Shell Companies
|
-
|
16.8
Composite
|
$10.72
|
Profitability
21.2
|
|
Shell Companies
|
-
|
50.4
Composite
|
$11.09
|
Growth
58.6
|
|
Shell Companies
|
-
|
49.6
Composite
|
$0.22
|
Growth
58.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
$15.52
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
HONDU
HCM II Acquisition Corp.
Shell Companies
|
-
|
35.0
Composite
|
-
|
Growth
39.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$13.90
|
No pillar score
-
|
|
Shell Companies
|
-
|
44.3
Composite
|
$10.80
|
Growth
59.6
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.18
|
No pillar score
-
|
|
Shell Companies
|
-
|
48.5
Composite
|
-
|
Profitability
54.8
|
|
HHGCU
HHG Capital Corporation
Shell Companies
|
-
|
48.5
Composite
|
-
|
Profitability
54.8
|
|
Shell Companies
|
-
|
49.6
Composite
|
-
|
Profitability
56.0
|
|
HLVX
HilleVax, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
28.8
Composite
|
$0.04
|
Profitability
50.0
|
|
Shell Companies
|
-
|
36.3
Composite
|
$5.00
|
Health
46.0
|
|
Shell Companies
|
-
|
24.7
Composite
|
-
|
Profitability
28.9
|
|
Shell Companies
|
-
|
24.4
Composite
|
-
|
Profitability
28.0
|
|
HUMAW
Humacyte, Inc.
Biotechnology
|
-
|
45.9
Composite
|
$0.01
|
Health
56.4
|
|
IMAB
I-MAB
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IKNA
Ikena Oncology, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IMTXW
Immatics N.V.
Biotechnology
|
-
|
49.6
Composite
|
-
|
Profitability
68.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
36.0
Composite
|
$2.31
|
Profitability
53.0
|
|
Shell Companies
|
-
|
36.0
Composite
|
-
|
Profitability
53.0
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
INZY
Inozyme Pharma, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
45.3
Composite
|
$10.40
|
Health
54.1
|
|
Shell Companies
|
-
|
43.0
Composite
|
$11.49
|
Health
54.1
|
|
Shell Companies
|
-
|
43.0
Composite
|
$0.05
|
Health
54.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.86
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$12.00
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.02
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$9.50
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$5.51
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
$0.10
|
No pillar score
-
|
|
ISRLU
Israel Acquisitions Corp
Shell Companies
|
-
|
31.4
Composite
|
$11.02
|
Health
49.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
IXQWF
IX Acquisition Corp.
Shell Companies
|
-
|
24.1
Composite
|
-
|
Efficiency
32.7
|
|
Biotechnology
|
-
|
49.8
Composite
|
$0.02
|
Health
64.5
|
|
JVSAU
JVSPAC Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
40.3
Composite
|
$0.02
|
Health
48.6
|
|
Shell Companies
|
-
|
40.3
Composite
|
$11.99
|
Health
48.6
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
53.7
Composite
|
$0.10
|
Growth
66.7
|
|
KRON
Kronos Bio, Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
61.5
Composite
|
$0.63
|
Profitability
68.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
LEXXW
Lexaria Bioscience Corp.
Biotechnology
|
-
|
40.1
Composite
|
$0.00
|
Efficiency
52.3
|
|
Biotechnology
|
-
|
49.6
Composite
|
$0.02
|
Efficiency
76.3
|
|
Shell Companies
|
-
|
21.2
Composite
|
$36.05
|
Growth
23.7
|
|
Shell Companies
|
-
|
61.4
Composite
|
$30.28
|
Growth
77.4
|
|
Shell Companies
|
-
|
21.2
Composite
|
-
|
Growth
23.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
MRUS
Merus N.V.
Biotechnology
|
-
|
51.8
Composite
|
$90.00
|
Profitability
60.4
|
|
Shell Companies
|
-
|
33.5
Composite
|
$0.02
|
Profitability
40.9
|
|
Shell Companies
|
-
|
24.2
Composite
|
$11.89
|
Health
29.5
|
|
Shell Companies
|
-
|
24.2
Composite
|
$11.50
|
Health
29.5
|
|
Biotechnology
|
-
|
50.0
Composite
|
$0.02
|
Profitability
67.2
|
|
MCAAU
Mountain
Shell Companies
|
-
|
41.8
Composite
|
-
|
Efficiency
50.7
|
|
MCAA
Mountain
Shell Companies
|
-
|
41.8
Composite
|
-
|
Efficiency
50.7
|
|
Shell Companies
|
-
|
41.8
Composite
|
-
|
Efficiency
50.7
|
|
Shell Companies
|
-
|
22.7
Composite
|
$10.92
|
Profitability
36.4
|
|
MURA
Mural Oncology plc
Biotechnology
|
-
|
54.4
Composite
|
-
|
Profitability
65.9
|
|
Shell Companies
|
-
|
42.6
Composite
|
-
|
Health
56.4
|
|
Shell Companies
|
-
|
42.6
Composite
|
-
|
Health
56.4
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
32.7
Composite
|
$0.08
|
Profitability
49.3
|
|
Shell Companies
|
-
|
28.4
Composite
|
-
|
Health
38.8
|
|
Shell Companies
|
-
|
28.4
Composite
|
-
|
Health
38.8
|
|
Shell Companies
|
-
|
29.9
Composite
|
-
|
Health
38.8
|
|
Biotechnology
|
-
|
52.9
Composite
|
$17.00
|
Profitability
61.2
|
|
Shell Companies
|
-
|
44.2
Composite
|
$0.08
|
Health
52.2
|
|
Shell Companies
|
-
|
46.2
Composite
|
$12.99
|
Health
52.6
|
|
Shell Companies
|
-
|
53.5
Composite
|
$10.65
|
Growth
58.5
|
|
Biotechnology
|
-
|
41.3
Composite
|
$0.03
|
Health
42.9
|
|
NLSPW
NLS Pharmaceutics Ltd.
Biotechnology
|
-
|
0.0
Composite
|
$0.02
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
48.5
Composite
|
$0.01
|
Profitability
66.9
|
|
NTRBW
Nutriband Inc. Warrant
Biotechnology
|
-
|
45.4
Composite
|
$0.35
|
Profitability
62.4
|
|
Shell Companies
|
-
|
41.9
Composite
|
$12.07
|
Health
46.3
|
|
Shell Companies
|
-
|
50.1
Composite
|
$11.00
|
Health
59.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
$0.14
|
No pillar score
-
|
|
OABIW
OmniAb, Inc.
Biotechnology
|
-
|
60.9
Composite
|
$0.09
|
Profitability
77.5
|
|
Biotechnology
|
-
|
50.1
Composite
|
-
|
Profitability
58.6
|
|
OPT
Opthea Limited
Biotechnology
|
-
|
33.0
Composite
|
-
|
Health
47.1
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
53.3
Composite
|
$0.01
|
Profitability
70.8
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
37.8
Composite
|
-
|
Valuation
100.0
|
|
Shell Companies
|
-
|
4.5
Composite
|
-
|
Profitability
18.0
|
|
Shell Companies
|
-
|
32.5
Composite
|
-
|
Efficiency
79.3
|
|
Shell Companies
|
-
|
32.5
Composite
|
$11.32
|
Efficiency
79.3
|
|
Shell Companies
|
-
|
32.5
Composite
|
$12.00
|
Efficiency
79.3
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
50.3
Composite
|
$10.81
|
Growth
59.2
|
|
Shell Companies
|
-
|
37.9
Composite
|
$11.00
|
Profitability
50.0
|
|
PRTG
Portage Biotech Inc.
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
42.5
Composite
|
$0.01
|
Efficiency
51.4
|
|
Biotechnology
|
-
|
47.7
Composite
|
$0.03
|
Profitability
72.9
|
|
Shell Companies
|
-
|
31.6
Composite
|
-
|
Health
47.5
|
|
Shell Companies
|
-
|
43.1
Composite
|
-
|
Health
47.2
|
|
Shell Companies
|
-
|
30.7
Composite
|
-
|
Health
44.4
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
46.6
Composite
|
$11.51
|
Growth
58.4
|
|
Shell Companies
|
-
|
45.5
Composite
|
$10.83
|
Growth
58.4
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
51.2
Composite
|
-
|
Profitability
72.8
|
|
Biotechnology
|
-
|
48.6
Composite
|
$0.01
|
Growth
67.5
|
|
Biotechnology
|
-
|
46.8
Composite
|
-
|
Growth
60.4
|
|
Biotechnology
|
-
|
45.6
Composite
|
$8.86
|
Efficiency
62.1
|
|
Shell Companies
|
-
|
57.8
Composite
|
$11.07
|
Profitability
70.5
|
|
RFAC
RF Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
RFACU
RF Acquisition Corp.
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
43.9
Composite
|
$10.77
|
Growth
54.7
|
|
Shell Companies
|
-
|
40.7
Composite
|
$7.60
|
Profitability
44.5
|
|
Biotechnology
|
-
|
56.2
Composite
|
$0.01
|
Growth
62.8
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
42.3
Composite
|
$0.05
|
Profitability
59.4
|
|
SIMAU
SIM Acquisition Corp I
Shell Companies
|
-
|
49.4
Composite
|
$10.92
|
Growth
58.8
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
38.0
Composite
|
$12.83
|
Health
47.5
|
|
Shell Companies
|
-
|
38.0
Composite
|
$1.65
|
Health
47.5
|
|
Shell Companies
|
-
|
43.1
Composite
|
-
|
Profitability
50.6
|
|
Shell Companies
|
-
|
41.0
Composite
|
$12.70
|
Health
47.0
|
|
Shell Companies
|
-
|
39.7
Composite
|
-
|
Health
47.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
47.6
Composite
|
$10.65
|
Profitability
50.9
|
|
SRZNW
Surrozen, Inc. Warrant
Biotechnology
|
-
|
45.2
Composite
|
$0.02
|
Profitability
52.1
|
|
Shell Companies
|
-
|
43.1
Composite
|
$10.73
|
Growth
58.2
|
|
Biotechnology
|
-
|
0.0
Composite
|
$0.50
|
No pillar score
-
|
|
Biotechnology
|
-
|
52.8
Composite
|
$0.01
|
Profitability
66.7
|
|
Biotechnology
|
-
|
0.0
Composite
|
$3.39
|
No pillar score
-
|
|
Biotechnology
|
-
|
45.0
Composite
|
-
|
Health
66.8
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
TRML
Tourmaline Bio, Inc.
Biotechnology
|
-
|
45.1
Composite
|
-
|
Health
65.2
|
|
Shell Companies
|
-
|
44.9
Composite
|
$12.57
|
Growth
77.8
|
|
TRVN
Trevena, Inc.
Biotechnology
|
-
|
37.4
Composite
|
$0.00
|
Profitability
53.5
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
VMCAU
Valuence Merger Corp. I
Shell Companies
|
-
|
45.9
Composite
|
$11.37
|
Profitability
59.1
|
|
Shell Companies
|
-
|
0.0
Composite
|
$11.74
|
No pillar score
-
|
|
VMCAW
Valuence Merger Corp. I
Shell Companies
|
-
|
0.0
Composite
|
$0.05
|
No pillar score
-
|
|
VRNA
Verona Pharma plc
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
47.1
Composite
|
$11.21
|
Growth
72.5
|
|
Biotechnology
|
-
|
44.3
Composite
|
-
|
Efficiency
61.1
|
|
Shell Companies
|
-
|
44.5
Composite
|
$14.50
|
Profitability
55.8
|
|
Shell Companies
|
-
|
30.9
Composite
|
$7.50
|
Profitability
44.6
|
|
Shell Companies
|
-
|
29.1
Composite
|
$10.00
|
Profitability
41.0
|
|
Shell Companies
|
-
|
58.7
Composite
|
$28.38
|
Growth
84.8
|
|
Shell Companies
|
-
|
25.2
Composite
|
$11.32
|
Profitability
31.1
|
|
Shell Companies
|
-
|
25.2
Composite
|
-
|
Profitability
31.1
|
|
Biotechnology
|
-
|
67.3
Composite
|
$24.98
|
Profitability
79.0
|
|
Biotechnology
|
-
|
67.1
Composite
|
$25.00
|
Profitability
79.0
|
|
Biotechnology
|
-
|
0.0
Composite
|
-
|
No pillar score
-
|
|
Shell Companies
|
-
|
38.6
Composite
|
$10.91
|
Profitability
47.9
|
|
Shell Companies
|
-
|
27.9
Composite
|
$2.00
|
Valuation
55.4
|
|
Shell Companies
|
-
|
23.8
Composite
|
$10.01
|
Profitability
43.4
|
|
Shell Companies
|
-
|
23.8
Composite
|
-
|
Profitability
43.4
|
Try a broader company name, ticker, sector, or industry keyword.
This framework combines industry-specific diagnostics, moat context, and peer benchmarks so each signal stays grounded in how this business model actually compounds.
We group pre-commercial biotech and similarly early-stage businesses into a separate framework because revenue, margins, and near-term profitability are often the wrong lens. The money-flow engine starts with cash on hand, then follows operating expense, R&D intensity, operating cash burn, financing inflows, and estimated runway.
That same logic carries into the broader StatsAlpha(TM) framework. The trade-off ledger for pre-revenue biotech is intentionally sparse in the current implementation: profitability is disabled, safety focuses on liquidity and cash position, and the code explicitly flags the need for future runway and burn-specific calculators. That is a feature, not a gap in judgment. The framework avoids pretending these businesses can be compared like mature cash generators.
On the moat and valuation side, biotech currently inherits broader corporate tools where needed, but the fair-value defaults also acknowledge the category's binary nature and note that a probability-of-success layer would be preferable to a smooth-growth DCF. In practice, this profile should be read as a disciplined way to track funding durability and upside optionality, not as a shortcut to certainty. This framework is for informational purposes only, not investment advice.
Each layer answers a different question: where value is created, what protects it, and how execution compares with the rest of the coverage set.
Benchmarks and narrative cues are meant to clarify what the framework is seeing in the data. They are not investment advice.
Coverage starts with the companies that actually operate inside this business model, so peer comparisons stay relevant instead of generic.
The Biotech / Pre-Revenue layer isolates the cash-flow mechanics, capital demands, and operating risk that matter most for this industry.
We then layer in Corporate Default, pillar ranges, and peer leaders to show what strong execution looks like relative to the broader cohort.